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SCOPE OF THIS THESIS 
 
Breast cancer is the second most common cancer in women. Breast cancer patients 
have a reasonable chance of becoming cured, particularly when they are diagnosed in 
an early phase. Eliminating primary tumors by surgery, chemotherapy, or radiation is 
quite successful. However, for metastases there is no cure. Thirty percent of the breast 
cancer cases will progress into metastatic disease, but they cannot be removed by 
surgery or radiation, and usually become chemoresistant. However, preclinical and 
clinical studies have shown that cancer vaccination has an effect on metastases but that 
a real breakthrough is hampered by the strong immune suppression in the tumor 
microenvironment (TME). Therefore, in this thesis we focused on the treatment of 
metastatic breast cancer using an attenuated Listeria monocytogenes (Listeriaat)-based 
vaccine expressing tumor-associated antigen (TAA) Mage-b, combined with adjuvants 
such as Curcumin or alphagalactosylceramide (!GC), to reduce immune suppression in 
the TME in order to improve the vaccine efficacy of Listeriaat-Mage-b. 
 
Chapter 1 gives an overall introduction on breast cancer, current therapeutic treatment 
options, cancer immunoediting, innate and adaptive immune responses against cancer, 
an overview of various cancer vaccines, and an introduction to the experimental work of 
this thesis.  
 
Chapter 2 describes the improvement of Listeriaat-Mage-b vaccination by Curcumin in 
mice with metastatic breast cancer through the reduction of IL-6. 
 
Chapter 3 describes the improvement of Listeriaat-Mage-b vaccination in mice with 
metastatic breast cancer by the incorporation of !GC into the Listeriaat cell wall. 
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Chapter 4 is a general discussion about the promises and problems of cancer 
vaccination, final conclusions about the vaccine studies performed, and future prospects 
of cancer vaccination. 
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CHAPTER 1 
 
INTRODUCTION 
 
Cancer 
Cancer is the uncontrolled growth of abnormal cells in the body. Cancerous cells are 
also called malignant cells. They can develop in almost any organ or tissue, such as the 
lung, colon, breast, skin, bones, spleen, thymus, or in the central nervous system. 
Moreover, many of the cancers metastasize to other organs, depending on the type of 
tumors and the tumor microenvironment. Metastases are tumor cells that escape from 
the primary tumor, and travel via the blood stream to different organs where they can 
home and grow into new tumors. Breast-, lung-, kidney- and testical cancer have been 
described as those with the highest incidence of metastases, and 30% of the breast 
cancers progress into metastatic disease1. Numerous factors may contribute to the 
development of cancer including chemicals, environmental toxins, genetic problems, 
viruses, radiation, obesity, and excessive sunlight exposure, as well as drinking excess 
alcohol.  
 
The Breast 
Morphologically, the breast is a cone with the base at the chest wall, and the apex at the 
nipple, the center of the nipple-areola complex (NAC). The superficial tissue layer 
(superficial fascia) is separated from the skin by 0.5-2.5 cm of subcutaneous fat (adipose 
tissue). The suspensory Coopers’s ligaments are fibrous-tissue prolongations that 
radiate from the superficial fascia to the skin envelope. The adult breast contains 14-18 
irregular lactiferous lobes that converge to the nipple, to ducts 2.0-4.5 mm in diameter; 
the milk ducts (lactiferous ducts) are immediately surrounded with dense connective 
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tissue that functions as support frame work. The glandular tissue of the breast is 
biochemically supported with estrogen; thus, when a women reaches the menopause 
(cessation of menstruation) and her body estrogen levels decrease, the milk gland tissue 
then atrophies, withers, and disappears, resulting in a breast composed of adipose 
tissue, superficial fascia, suspensory ligaments, and the skin envelope. A schematic 
view of the breast tissue organization and mammary gland structure is shown in Figs 1 
and 2, respectively. 
 
Breast Cancer 
Breast cancer is the most frequently diagnosed cancer and the second leading cause of 
cancer death among females2. Most recent statistics estimated 230,480 new cases of 
the invasive breast cancer occurring among women during 2011 and about 2,140 new 
cases in men in the USA. For the year 2012, almost 39,970 deaths due to breast cancer 
are expected along with 226,870 new cases in the USA. 
 The most important risk factors that contribute to the development of breast 
cancer are family history (mutations in BRCA1/2 or p53 genes), prolonged exposures to 
endogenous or exogenous estrogens, alcohol, overweight, and physical inactivity 
(http://www.who.int/cancer/detection/breastcancer/en/index2.html). Other risk factors include 
dietary effects combined with late first childbirth, lower parity and shorter breastfeeding. 
Finally, the age factor is important, not only for breast but for most types of cancer. 
 
Various types of breast cancer 
Ninety five percent of all breast cancers are carcinomas, i.e. they arise from epithelial 
origin3. Breast cancer can be divided into two major types, i.e. non-invasive and invasive 
breast cancer.  
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Non-invasive breast cancer. The most prevalent type of non-invasive breast cancer is 
ductal carcinoma in situ (DCIS), and starts in the tubes (ducts) that move milk from the 
breast to the nipple. This type of cancer does not extend beyond the basement 
membrane and has a low potential for metastases. The second type of non-invasive 
carcinoma is lobular carcinoma in situ (LCIS) that arises and is confined to the milk 
producing glands or lobules3. The proportion of LCIS in benign breast disease is low, 
ranging between 0.5% and 4%4, but it may progress to invasive cancer if untreated. 
Lobular carcinoma in situ (LCIS) is a marker for an increased risk of invasive cancer in 
the same or both breasts. 
Invasive breast cancer. This is the type of cancer that spreads outside the basement 
membrane of the lobule or duct into the breast tissue. Invasive breast cancer will either 
remain localized to the breast or metastasize to other parts of the body, mostly lymph 
nodes, brain, bones, liver, or lungs and progresses into metastatic breast cancer. About 
80% of all breast cancers are invasive ductal carcinomas (IDC), while 10–14% of all 
breast carcinomas are invasive lobular carcinoma (ILC)5. Furthermore, inflammatory 
breast carcinoma (IBC) is a form of rapidly progressing primary skin changes such as 
erythema, skin thickening, orange peel skin, and nipple retraction6. The unique 
appearance of IBC is due to tumor emboli that readily metastasizes into and block 
lymphatic vessels of the skin overlying the breast7.  
 
Molecular classification of breast cancer 
Breast cancer has a heterogeneous phenotype. Tumors comprise of various distinct cell 
types with different biological features and clinical behavior. Therefore, breast cancer 
has been further classified based on different molecular techniques and genetic profiling 
into five major subtypes of breast cancers: basal-like, luminal A, luminal B, HER2+/ER–, 
and normal breast–like8-10. These five subtypes have distinct clinical outcomes. Luminal 
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A-type tumors have the best prognosis and are low-grade tumors9, while luminal B type 
tumors are usually more aggressive demonstrating more proliferation and considered as 
high-grade tumors. Basal-like tumors usually have the worst prognosis. Most of the 
basal-like tumors poorly respond to therapy because they are often triple-negative (TN) 
for Estrogen Receptor (ER), progesterone receptor (PR), and HER2/neu. HER2 (human 
epidermal growth factor receptor) is overexpressed in 20-30% of the breast cancer 
cases. However, during HER2-targeted treatment its expression disappears, and 
therefore these patients are no longer susceptible to HER2-targeted therapies. About 
20% of all breast cancers are TN, and TN breast cancer is particular increased in black 
women11. TN breast cancer is often associated with regional node metastases12. The 
molecular profiling of these subtypes of breast cancer helps to determine an optimal 
therapy regimen for the patients.  
 
Treatment Options 
Over the last decade, treatment of breast cancer has been dramatically improved. 
However, for metastatic breast cancer there is no cure. The treatment of choice depends 
on various factors such as the stage of cancer, the type of cancer, the genetic profile of 
the cancer (mutations in target genes), and whether the patient’s tumor expresses ER, 
PR, and/or HER2/neu. The treatment options can be divided in local or systemic 
treatment. Local treatments involve the area of the disease only. Radiation and surgery 
are forms of local treatment. Systemic treatments affect the entire body. Chemotherapy 
is a type of systemic treatment. Most women receive a combination of treatments. For 
women with Stage I, II, and III breast cancer, the main goal is to treat the cancer and 
prevent it from returning (curing). For women with stage IV breast cancer, the goal is to 
improve the symptoms and help them to live longer. In most cases stage IV breast 
cancer cannot be cured. The various stages of breast cancer are defined as follow. 
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Stage I: This is the earliest stage of invasive breast cancer. At this stage, the cancer 
cells have spread beyond the original location and into the surrounding breast tissue. 
Stage II: This stage is a slightly more advanced form of stage I breast cancer. The 
cancer cells have spread beyond the original location and into the surrounding breast 
tissues, and the tumor is larger than in stage I diseases. However, stage II means the 
cancer has not spread to a distant part in the body. Stage III: This is a more advanced 
form of invasive breast cancer than stage II. The breast cancer cells have usually not 
spread to distant sites of the body, but they are present in several axillary (underarm) 
lymph nodes. The tumor may also be quite large at this stage, possibly extending to the 
chest wall or the skin of the breast. Stage IV: Stage IV means that the cancer has 
spread elsewhere in the body. The affected areas may include the bones, brain, lungs or 
liver, and more than one part of the body may be involved. For more detailed information 
see http://www.cancercenter.com/breast-cancer/breast-cancer-staging/stage-0-breast-
cancer.cfm.  
 
Local Treatment 
 
Surgery. Surgery is advised for women with a localized breast tumor smaller than 4 cm. 
Surgery can be divided in lumpectomy, partial mastectomy, total mastectomy, or radical 
mastectomy and depends on the stage and type of breast cancer.  
 
Lumpectomy involves removal of the tumor in the breast along with the negligible 
amount of surrounding tissue. Another version, partial mastectomy is more extensive 
and removes a larger amount of normal tissue surrounding the tumor. These two 
surgical procedures constitute ‘breast conserving surgery’ as removal of the complete 
breast is avoided, and is advised for patients with stage I or II breast cancer. Patients 
with a more advanced stage of breast cancer may undergo a total mastectomy or 
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complete removal of the breast and a sentinel lymph node (first node in the chain that 
forms the regional lymphatic system) biopsy. Sentinel lymph node biopsy may predict 
axillary node metastasis in breast cancer. If more advanced, tumor radical mastectomy 
is advised that includes removal of both breasts along with removal of lymph nodes in 
the armpits and chest. Surgery is the preferred mode of treating breast cancer when 
accompanied with radiotherapy or chemotherapy. For a review see Apantaku, 200213. 
 
Radiation therapy. Surgical removal of a tumor is often followed by radiation therapy13. 
Clinical trials of breast conservation surgery alone or surgery plus radiation showed 
higher recurrence rate in women who did not receive radiation14. 
 
Systemic treatment 
When compounds are administered through the blood vessels or orally, it is considered 
as systemic therapy. These compounds include chemotherapy, hormones, or more 
targeted therapies with small molecules, specific enzymes, or antibodies. 
 
Chemotherapy. Chemotherapy is often advised for women with hormone receptor-
negative invasive breast cancer. Although usually given through the blood stream or 
orally, it can also administered regionally in the area where the cancer cells are such as 
in the abdomen, cerebrospinal fluid, or an organ. To completely eliminate the primary 
tumors, standard chemotherapy regimen involves a combination of various 
chemotherapeutica. Most widely used combination therapies are Adriamycin 
(Doxyrubicin) and cyclophosphamate/Taxol, Adriamycin, and cyclophosphamide 
(AC/TAC), or cyclophosphamide, methotrexate, and fluorouracil/cyclophosphamde, 
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adriamycin and fluorouracil (CMF/CAF), or epirubicin and 
cyclophosphamide/cyclophosphamide, epirubicin and fluorouracil (EC/CEF), or taxotere 
and cyclophosphamide/taxotere, cycophosphamide and herceptin (TC/TCH). Complete 
recovery is usually between 60-100% of the patients receiving this combination 
therapies15,16  
 
Hormone therapy. Hormones such as estrogens or receptors such as HER2/neu 
(epidermal growth factor receptor) are involved in the growth of breast cancer cells. 
Hormone therapy blocks the interaction between the hormone present in blood and their 
receptors on the tumor cells, thereby preventing the tumor cells from growing. For 
instance, tamoxifen is usually given to patients with early stage estrogen receptor-
positive breast cancer. Another form of hormone-targeting therapy is aromatase 
inhibitors, that blocks the production of estrogen, and is often given to post-menopausal 
women with estrogen-dependent breast cancer17. 
 
Targeted treatment. Targeted therapy is a newer type of cancer treatment. This therapy 
uses special anti-cancer drugs that target certain changes in a cell that can lead to 
cancer. These therapies are directed against pathways specifically involved in the 
development of cancer such as proliferative signaling, escaping immune destruction, 
promoting invasion and metastases, and resisting cell death. Although initial results of 
clinical trials with therapies targeting HER2 in metastatic breast cancer using 
Trastuzumab combined with chemotherapy, were highly promising, the majority of these 
patients become resistant18. Clinical trials with HER2/1 inhibitors such as Perutuzumab, 
and with HER2/3 or HER1/2/4 inhibitors such as Neratinib, in combination with 
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Trastuzumab and chemotherapy, are under way19,20. Lapanitib, a HER1/2 inhibitor, is 
more promising when combined with Trastuzumab, with less severe side effects than 
most conventional therapies21. While all these therapies are promising in patients that 
express the HER1/2/3/4, triple-negative patients with tumors and metastases lacking 
expression of receptors for estrogen, progesterone, and HER2, have the poorest 
prognosis because they will not responding to these therapies, and other types of 
therapies are under investigation but with moderate success. One such therapy is an 
anti-angiogenic therapy, which appeared to have less effect on overall survival than 
expected and data explaining this lower efficacy are not available yet. So far, the most 
successful anti-angiogenic therapy with tyrosine kinase inhibitor Sunitinib, targeting the 
vascular endothelial growth factor (VEGF) receptor, platelet-derived growth factor, c-kit, 
and Flt2, induce serious side effects22, while Bevacizumab, a human antibody to VGEF, 
prolonged progression-free survival, but not the overall survival time. Another type of 
therapy is Poly (ADP-ribose) polymerase-1 (PARP) inhibitors inducing DNA repair 
defects in tumors but not in normal cells. Such therapy has potential23 but is effective in 
BRCA1/2-mutants patients only, which makes up 0.1-0.8% of the general population24. 
The most promising targeted therapies are shown in Fig 3. In summary, little progress 
has been made over the last 25 years in the development of effective therapies against 
metastatic breast cancer. This underlines the urgent need for new alternative therapeutic 
approaches. One such alternative therapy could be cancer immunotherapy or 
vaccination.  
 
Immune surveillance 
In 1909, Paul Ehrlich predicted that the immune system repressed the growth of 
carcinomas that would otherwise occur with great frequency (Ehrlich P. Ned Tijdschr
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Geneesk 5: 273-290, 1909). This statement initiated a contentious debate over 
immunologic control of neoplasia. Fifty years later, Burnet stated that tumor cell-specific 
neo-antigens could provoke an effective immunologic reaction that would eliminate 
developing cancers25-27, while Thomas stated that complex long-lived organisms must 
posses mechanisms to protect against neoplastic disease similar to those mediating 
homegraft rejection (Thomas L. Discussions in cellular and humoral aspects of the 
hypersensitivity states, 1959). With the functional demonstration of tumor-specific 
antigens in the mouse, supporting the ideas of Ehrlich, Thomas, and Burnet, the 
immunosurveillance theory developed, which stated that sentinel thymus-dependent 
cells of the body constantly surveyed host tissues for nascently transformed cells. 
However, there has been a growing recognition that immune surveillance represents 
only one dimension of the complex relationship between the immune system and 
cancer28. Recent work has shown that the immune system not only protects against the 
development of primary non-viral cancers but also sculpts tumor immunogenicity, which 
developed into a new hypothesis of “cancer immunoediting”.  Cancer immunoediting is a 
process that consists of three phases, i.e. elimination (cancer immunosurveillance), 
equilibrium, and escape29.  
 
Elimination of cancer cells (cancer immunosurveillance)  
Various studies have shown that deficiencies in key immunological molecules such as 
IFN! and perforin enhanced hosts susceptibility to both chemically induced and 
spontaneous tumors, demonstrating the cancer immunosurveillance hypothesis30-35. 
Compelling data suggest that the immunosurveillance is not restricted to mouse models 
but also exists in humans28,29. These studies raised the question as to how cancer 
immunosurveillance functions as an extrinsic tumor suppressor and protects the immune 
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competent host from developing neoplasia. For instance, which cells of the immune 
system are involved in the protection tumor of development, what are the key molecules 
of the immune system in cancer immunosurveillance, and how does the immune system 
distinguish between a transformed cells and its normal progenitor?  
 
Cancer immune surveillance by adaptive and innate immune cells. When tumor cells 
develop (by mutation of genes induced through environmental influences or hereditary), 
hormones as discussed at the beginning of this thesis), proteins on their membrane 
change which leads to their elimination by the innate and adaptive immune system 
during the phase of immunosurveillance. The innate immune system reacts in the early 
phase to danger signals and does not involve specific antigen recognition while the 
adaptive immune system reacts to specific antigens such tumor-associated antigens 
(TAA). NK cells, NKT cells, !"T cells, tumor-associated macrophages (TAM), and 
myeloid-derived cells such as immature granulocytes and monocytes, also called 
myeloid-derived suppressor cells (MDSC), belong to the innate immune system. MDSC 
are particularly important in cancer and will be discussed later in this thesis. CD4 and 
CD8 T cells, as well as B cells, belong to the adaptive immune system. Below the role of 
these different cell types in anti-tumor reactions has been discussed. For a review see 
Dunn et al, 200429. A schematic view of immune cells of the innate and adaptive immune 
system against cancer is shown Fig 4. 
 
T cells. Cytotoxic T lymphocytes (CTL) are considered to be the most important players 
of the adaptive immune system in anti-tumor reactions. CTL are CD3+CD8+ and express 
the #$ T cell receptor (TCR) that recognizes tumor-associated antigens (TAA) in 
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association with major histocompatibility complex (MHC) molecules on the tumor cells. 
As has become evident from in vitro studies, these CTL are activated when exposed 
simultaneously to both TAA/self-MHC complexes and co-stimulatory molecules, resulting 
in CTL-mediated tumor cell cytolysis. However, anti-tumor responses can also be 
inhibited by co-inhibitory molecules. An overview of co-stimulatory and inhibitory 
molecules is shown in Fig 5AB. Key components of CTL in killing tumor cells are IFN! 
and perforins30,35. CD4 T cells, also called “helper T cells”, recognize TAA through MHC 
class II molecules, and upon activation they produce large amounts of interleukin (IL)-2, 
which is a growth factor and activator of CD8 T cells. CD8 T cell responses to TAA will 
be central in this thesis and will be later discussed in more detail. In contrast to CD4 
helper T cells, also regulatory CD4 T cells (Treg) are involved in anti-tumor responses. 
However, instead of helping the CD8 T cells, they inhibit the responses of CD8 T cells36. 
Treg are characterized by the expression of CD4, CD25 and Foxp3. It has been reported 
that Tregs can act antigen-dependent and -independent 
36,37  
 
NK cells. NK cells are TCR-CD3-CD4-CD8-CD11b+CD16+(CD56+) and they participate in 
cancer immunosurveillance. They express NKG2D-activating receptors that react with 
ligands often over expressed on tumors such as MICA/B, and Rae-1, H60, or MULT-138-
40, and become cytolytic in the presence of IFN!, IL-2, TNF#29. In contrast to CTL, their 
responses are TAA-independent and they can kill tumor cells with low or no MHC 
expression. NK cells can also kill tumor cells through antibody-dependent cellular 
cytotoxicity through their Fc receptors that can interact with antibodies that recognize 
antigens on tumor cells. Mice depleted for NK cells were three times more sensitive for 
methylcholantrene (MCA)-induced cancers than wild type mice41, demonstrating its role 
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in anti-tumor responses. Also in this thesis we will show that NK cells can be activated in 
mice with metastatic breast cancer. 
 
NKT cells. Natural killer T (NKT) cells also participate in cancer immunosurveillance, but 
react as first line of defense. The most widely studied group of NKT cells expresses the 
invariant type of the TCR (V#14J#18/V$2, 7, or 8 in the mouse and V#24J#18/V$11 in 
humans)42, CD3, CD56, NK1.1 and produce granzyme B43. NKT cells recognize 
glycolipids, presented by a MHC-like molecule CD1d44. They are particularly interesting 
because when activated they form the bridging link between the innate and adaptive 
immune system upon activation. This occurs through the production of a whole array of 
cytokines (proteins secreted by cells that regulate the immune system) including IFN!, 
IL-12, IL-4, and IL-13, that can activate other cells of the innate and adaptive immune 
system against cancer45. Like NK cell depletion, it has been shown that mice depleted of 
NKT cells were three times more susceptible to MCA-induced cancers than wild type 
mice46. In this thesis we will show that NKT cells stimulated with a synthetic glycolipid 
alphagalactosylceramice (#GC), produce cytokines in correlation with improved TAA-
specific T cell and NK cell responses in mice with metastatic breast cancer.  
 
!"T cells. !"T cells are CD3+TCR!+"+, CD8+ and react as a first line defense like NK and 
NKT cells. Upon activation they produce large amounts of IFN!29. 
 
MDSC. Myeloid-derived suppressor cells (MDSC) play an important role in cancer, and 
particularly in metastatic cancer. They are immature myeloid cells that differentiate into 
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mature granulocytes, macrophages, and DC. In cancer patients, MDSC migrate from the 
bone marrow via the blood stream to the primary tumor. These primary tumors block their 
differentiation and activate these immature cells to produce immune suppressive factors 
such as arginase I, inducible nitric oxide synthetase (iNOS), and reactive oxygen species 
(ROS). Cytokines such as IL-6, IL-10, and TGF$ are also produced by MDSC, which are 
able to down regulate antigen-specific and non-specific T cell responses in the TME47,48. 
In mice, MDSC express both the myeloid lineage differentiation antigen Gr1 (Ly6C and 
Ly6G) and the #M integrin CD11b. Two major groups of MDSC have been described: 
CD11b+Gr1high (CD11b+Ly6G+Ly6Clow) with a granulocytic phenotype (gMDSC), and 
CD11b+Gr1low (CD11b+Ly6G-Ly6Chigh) with a monocytic phenotype (mMDSC)49,50. Both 
mMDSC and gMDSC are immunosuppressive but may have different functions at the 
tumor site. 
 
TAM. Tumor-associated macrophages (TAM) play an important role in the TME. They 
express M2-associated pro-tumoral functions, such as angiogenesis, matrix remodeling 
and suppression of the adaptive immune system51. TAM produce chemokines (a family 
of small cytokines or proteins) such as CCL2, M-CSF, and VGEF involved in the 
recruitment of monocytes, and differentiation into TAM, as well as CSF, IL-4, IL-10, and 
TGF$52. These latter two cytokines are involved in the suppression of Th1 responses 
and naïve T cell responses through the recruitment of Tregs
52. TAM are also involved in 
the development of angiogenesis through the production of VGEF, PDGF, TGF$ and 
members of the FGF family53-55. 
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Key molecules of the immune system in cancer immunosurveillance. IFN! produced by T 
cells, NK cells, NKT cells, !"T cells, and macrophages are relevant effector molecules in 
cancer immunosurveillance. For instance, endogenous production of IFN! protected 
against transplanted, chemically induced and spontaneous tumors30-32,35. Also blocking 
the IFN! receptor IFNGR1 with Abs resulted in faster tumor growth or enhanced the 
sensitivity for developing MCA-induced tumors with 10-120 times56. As mentioned above 
!"T cells are physiologically a relevant source of IFN! in the cancer immunosurveillance 
process. IFN! activates the innate and adaptive anti-tumor immune responses56. For 
instance, IFN! promotes the generation of tumor-specific CD4+ Th1 T cells and CTL and 
activates cytocidal activity in macrophages. Moreover, IFN! inhances the 
immunogenicity of tumors through the upregulation of MHC class I molecules31.  
 
The other important key molecule in cancer immunosurveillance is perforin. Perforin is a 
lytic enzyme, produced by CD8 T cells and NK cells, which when it comes in contact 
with tumor cells perforates the cell membrane resulting in tumor cell death57. Granzyme, 
a family of structurally related serine proteases, is secreted by NKT cells through 
exocytosis, and induces apoptosis of target cells57. 
 
Also IL-12 is important in cancer immunosurveillance. IL-12 is a heterodimer cytokine 
composed of two subunits, #-chain and a $-chain, both covalently linked by a disulfide 
bridge, and coded as IL-12p35 and IL-12 p40, respectively58. IL-12 is primarily produced 
by activated macrophages, monocytes, neutrophils, and DC59, and strongly activates 
CTL and NK60. IL-12 activates naïve and mature T cells61,62. IL-12 has great anti-tumor 
activity, particularly against metastases63,64. IL-12 also possesses anti-angiogenic 
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activities65-67. Anti-tumor effects of IL-12 have been found in various mouse tumor 
models such as B16 melanoma, CT26 colon carcinoma, Renca renal-cell carcinoma, 
TSA mammary carcinoma, SCK mammary carcinoma, and many others65,68. While 
recombinant IL-12 is toxic65,69, IL-12 produced by the immune system itself through 
stimulation has no side effects, as we found in our breast cancer model (see chapters 2 
and 3).  
 
Equilibrium 
Originally, cancer immunosurveillance was considered to protect the host from cancer27, 
by eliminating tumor cells at least at the earliest stage of cancer. This is correct for 
immunogenic tumor cells at a stage that immune suppression has not been induced yet. 
However, there is an equilibrium phase between the tumor cells and the immune 
system. Tumor cells may become non-immunogenic by loosing TAA expression through 
genetic instability70, a well known problem in cancer, or by cytokine production such as 
TGF$ which reduces MHC class I expression levels on tumor cells71. The tumor cells 
that remain start producing cytokines or factors such as GM-CSF or S10072,73 or other 
factors that recruit MDSC, or cytokines such as IL-10 that induce differentiation of blood 
monocytes into tumor-associated macrophages (TAM), or M2 macrophages74,75.  These 
immune cells starts suppressing the adaptive and innate immune system, and at this 
point not only the non-immunogenic will enter the escape phase, but also immunogenic 
tumor cells since MDSC, TAM and M2 macrophages prevent the immune system from 
eliminating tumor cells.  
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Escape of tumor cells 
Once in the escape phase, there is a strong interaction between tumor cells and MDSC, 
TAM and M2 macrophages, resulting in the production of high levels of cytokines and 
factors that suppresses the immune system such as IL-6, IL-10, TGF$, iNos, 
arginase51,72,76,77, and finally leading to escape of the tumor cells from the immune 
system. All those cells that normally can eliminate the tumor cells directly or indirectly 
such as CD8 and CD4 T cells, as well as NK cells, NKT cells, !"T cells are now 
functionally inhibited. This is the moment that tumors develop, and in a later phase 
depending on the tumor microenvironment and the type of tumor, metastases will 
develop. For a schematic view of the elimination of tumor cells, equilibrium and escape 
of tumor cells see Fig 6. For a review about the immunoediting theory see Dunn et al, 
200429  
 
Cancer vaccination 
While immunosurveillance is able to eliminate tumor cells in an early phase, there is a 
moment as discussed above that the immune system fails. This is the moment were 
vaccines or immunotherapy can help the immune system to eliminate the tumor cells by 
reducing immune suppression, by the generation of cytokines that can stimulate the 
immune system, and by the delivery of TAA molecules at large numbers into antigen-
presenting cells in vivo, which is the central theme of this thesis. While standard 
therapies such as chemotherapy, radiation, surgery or targeted therapies fail to eliminate 
metastases, cancer vaccination may be the best and most benign option for preventing 
or curing metastatic cancer.  
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Various cancer vaccines 
Developing bacterial or viral vaccines is different from developing cancer vaccines. 
Bacteria or viruses express membrane antigens that are foreign to the human immune 
system, and are therefore able to activate the immune system against these antigens. 
Tumors do not express foreign membrane antigens in the same way as bacteria or 
viruses because tumors are derived from normal human cells, expressing primarily the 
same antigens as normal cells do. However, several decades of research into the 
presence of tumor-specific antigens have shown that many tumors express antigens that 
are not expressed in normal adult tissues except testis and placenta. Examples are 
MAGE, GAGE, BAGE, LAGE, NY-ESO-178-81; overexpress antigens that are present at 
low levels in normal tissues, such as CEA, HER/neu-2, MUC182-84; or show altered 
antigen expression by mutation in cellular genes, such as MUM1, cdk4, ß-catenin85-87. 
These TAA are able to activate specific T cells if optimally presented (see below), and 
are therefore suitable targets for the development of cancer vaccines. For a schematic 
overview of more various TAA see Table 1. 
 
The first attempts to develop cancer vaccines on the basis of irradiated tumor cells were 
unsuccessful88. Tumor cells are poor antigen-presenting cells (APCs) due to the low 
expression of MHC and co-stimulatory molecules and poor processing of antigens and 
presentation of TAA on the membrane. Over the last decade, new generations of TAA-
based cancer vaccines have become available that are much more powerful in activation 
of the immune system than irradiated tumor cells. This new generation of vaccines is 
able to activate different T cells depending on processing of exogenous or endogenous 
proteins produced by the vaccine, and subsequent presentation of the antigen (TAA 
peptides) by APC to the immune system. Endogenous proteins, for instance delivered 
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into the cytoplasm of an APC by a DNA vaccine, are processed by cytoplasmic enzymes 
resulting in small peptides, then transported to the endoplasmic reticulum, where 
peptides can associate with newly synthesized MHC class I molecules. These 
peptide/MHC class I complexes migrate to the membrane of the APC for presentation to 
the immune system and for subsequent activation of naive CTL. Exogenous proteins, for 
instance from purified protein or conjugate vaccines, are internalized by APC via 
endocytosis to an endosomal compartment, where they are digested into peptides and 
associated with MHC class II molecules. These peptide/MHC class II complexes migrate 
to the membrane of the APC for presentation to the immune system and for subsequent 
activation of naïve T helper cells. However, exogenously produced proteins can also be 
taken up by APC and then presented in the context of MHC class I molecules (epitope 
spreading)(for a review see Cohen et al., 1998)89. Below, several cancer vaccines will be 
discussed that are particularly powerful in the induction of CTL responses.  
 
Peptide-based vaccines 
Use of peptide-based vaccines is an approach to initiate TAA-specific CTL responses. 
Such vaccines obviate the need to digest proteins into peptides, a process that is often 
impaired in tumor cells. Peptide-based vaccines consist of dendritic cells (DC) (isolated 
from the cancer patients themselves) loaded with synthetic peptides derived from TAA 
that are expressed, but inadequately presented by the tumor. These peptides assemble 
with MHC molecules that are highly expressed at the cell membrane of DC. Injection of 
these peptide-loaded DC into cancer patients leads to presentation of TAA-peptide/self-
MHC complex to the immune system, activating TAA-specific CTL, resulting in the 
destruction of TAA-expressing tumor cells. Clinical trials in patients with melanomas, 
prostate cancer, B-lymphomas or multiple myelomas using DC/peptide vaccines have 
been promising90. However, a major disadvantage of their use is that the production 
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procedures are difficult, expensive and time-consuming. Indeed, the DC need to be 
isolated from the cancer patient, expanded in vitro, then loaded with peptide and then re-
injected into the patient, all under sterile conditions. It is difficult to obtain sufficient viable 
DC with this approach. To circumvent these difficulties, several clinical trials in patients 
with melanomas, AIDS, breast, ovarian, or colorectal carcinomas, have been performed 
with some success using TAA-peptides without DC but in the presence of cytokines 
such as IL-2 and GM-CSF (for a review see Gravekamp)91. It is difficult to load DC with 
peptides in vivo, because the injected peptides need to compete with existing peptides 
associated with the MHC molecules at the membrane of DC. 
 
Tumor cell-dendritic cell hybrid vaccines 
Generation of hybrids between autologous tumor cells and allogeneic (monocyte-
derived) DC, presenting antigens expressed by the tumor in concert with co-stimulating 
capacities of DC is another approach to activate TAA-specific CTL92. An advantage is 
that unknown tumor antigens are included in this type of vaccine. Caution must be taken 
to avoid activating autoimmunity against normal cells93,94. These hybrids demonstrated 
the induction of MHC class I-restricted CTL reactive with MUC1 TAA. A human clinical 
vaccine trial with this tumor cell-dendritic cell hybrid vaccine showed promising results in 
metastatic breast cancer (for a review see Gravekamp)91, but the procedures are as 
difficult as with peptide-based vaccines.  
 
Delivery through DNA vectors 
Use of DNA vaccines allows activation of TAA-specific CTL. Like the above described 
DC-based vaccines, DNA-based vaccines circumvent the poor APC function of the 
tumor cells since the antigens delivered by the DNA vaccines will be presented by 
professional APC that do express high levels of MHC and co-stimulatory molecules. A 
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conventional DNA vaccine is a bacterial plasmid (for instance pCDNA3.1) containing an 
eukaryotic promoter (required for transcription), a Kozak sequence (required for 
translation) and the gene of interest, followed by a polyadenylation signal (to prevent 
degradation of mRNA). The gene of interest can be any DNA sequence that may 
activate tumor-specific T cell responses.  
 
Intramuscular or epidermal immunization with a DNA vaccine leads to DNA uptake into 
APC such as bone marrow-derived DC, macrophages, or Langerhans cells95. CpG rich 
motifs (high frequency of unmethylated CG sequences) present in bacterial DNA, enable 
stimulation and maturation of APC96. APC express pattern recognition receptors (PRR) 
that bind CpG rich motifs97. It might be speculated that interaction between CpG motifs 
and PRR may lead to internalization of the DNA vaccine like internalization of proteins, 
but unlike proteins might escape degradation. Circular DNA is less prone to degradation 
than linear DNA. In addition, it has been shown that cell types other than APC are 
involved in DNA uptake as well89. For instance, intramuscular injection of a DNA vaccine 
leads to the uptake and expression of the DNA vaccine in myocytes. However, myocytes 
do not function as APC, because they lack the important co-stimulatory molecules 
required for priming of naïve T cells. Epidermal DNA immunization allows the uptake of 
the DNA vaccine in keratinocytes. Keratinocytes, like myocytes, do not function as APC. 
It has been suggested that myocytes and keratinocytes deliver soluble antigen 
(exogenous) to APC, resulting in antigen presentation in context with MHC Class I or II 
molecules, resulting in activation of naïve CTL, or T helper cells, respectively. 
Cutaneous bombardment with DNA, using the gene gun is different from epidermal or 
intramuscular immunization98. It results in direct delivery (physically) of the DNA into the 
cytoplasm of Langerhans cells. These DC migrate to regional lymph nodes in order to 
present antigens delivered by the DNA vaccine to naïve CTL.  
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mRNA-based vaccines 
mRNA-based vaccines can code for all types of proteins, are easy and cost efficient to 
produce, have a favorable safety profile and enables the induction of combined immune 
responses99. Over the last few years major developments have been made in the field. 
Clinical approaches use mRNA either for direct administration or for engineering of 
adoptive transferred dendritic cells. However, there are still challenges to overcome such 
as the short half-life of extracellular mRNA, and relatively weak target specific immune 
responses100,101. 
 
Delivery through live attenuated viruses or bacteria  
An efficient delivery of TAA in vivo is a key issue for developing strong immune 
responses against cancer. In this regard, live vaccination strategies including various 
attenuated live bacterial and viral vectors have attracted great attention. Several 
attenuated bacterial strains such as Salmonella, Lactococcus lactis, and Listeria 
monocytogenes have been tested for the delivery of antigens in vivo102-105. Also viruses 
as vaccine vectors have been used such as Vaccinia, Adenovirus, Herpes Simplex virus, 
Paramyxovirus, and Retroviruses102,106,107. Even non-pathogenic variants of parasites 
such as Leishmania tarentolae, Toxoplasma gondii, and Trypanosoma cruzi has been 
used for gene delivery in vivo108,109. These bacteria, viruses and parasites have great 
potential to deliver target genes in vivo. However, safety aspects are still an issue, 
particularly for viruses and much less for bacteria and parasites. An overview of the 
different cancer vaccines in human clinical trials is shown in Table 2. 
 
Listeria monocytogenes 
In our laboratory, we used a highly attenuated Listeria monocytogenes (Listeriaat), for the 
delivery of TAA into APC. This Listeriaat was originally developed in the laboratory of Dr. 
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Yvonne Paterson, University of Pennsylvania, PA. She attenuated the Listeria bacteria 
to reduce the pathogenicity as described below. Listeriaat consists of Listeria plasmid 
pGG34 and a Listeria background strain XFL-7. The Listeria plasmid pGG34, expresses 
the positive regulatory factor (prfA) and Listeriolysin O (LLO)110. prfA regulates the 
expression of other virulence genes, and is required for survival in vivo and in vitro110. 
The coding region for the C-terminal part of the LLO (cytolytic domain that binds 
cholesterol in the membranes) protein in the plasmid has been deleted, but Listeriaat is 
still able to escape the host vacuole111. Mutations have been introduced into the prfA 
gene and the remaining LLO (expressed by the pGG34 vector), which further reduced 
the pathogenicity of Listeriaat 111.  
 Initially, we used the Listeriaat because it naturally infects professional APC 
(monocytes), and targets antigen delivery to both the class I MHC pathway of 
endogenous antigen presentation and the class II MHC pathway of exogenous antigen 
presentation. This DNA delivery system (containing the same antigen as expressed by 
the tumors) successfully protected mice from renal or colorectal tumors112. Advantages 
of Listeriaat are the higher efficiency of DNA uptake into APC and subsequent 
processing and antigen presentation compared to the conventional DNA immunizations 
described above, and the possibility of oral administration. We found that preventive 
vaccinations with Listeriaat expressing TAA Mage-b protected mice from metastatic 
breast cancer113.  
 Later our lab discovered that Listeriaat also infects tumor cells in vitro and in vivo, 
and kills tumor cells through the generation of high levels of reactive oxygen species 
(ROS) without side effects114. This was possible because Listeriaat survives and 
multiplies in the tumor microenvironment because of the strong immune suppression114, 
but is efficiently cleared in normal tissues that lack immune suppressions by 
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macrophages, NK cells and T cells115,116. These various pathways of Listeriaat are highly 
attractive for the development of cancer therapies. 
Most dramatically were the semi-therapeutic immunizations (one before and two 
after tumor development) with Listeriaat expressing TAA Mage-b114. This resulted in the 
complete elimination of all metastases and the primary tumor was reduced by 95%. This 
high efficacy of Listeriaat-Mage-b was obtained by the generation of excellent T cell and 
NK cell responses, and the direct kill of tumor cells by Listeriaat-induced ROS. The 
strong T cell and NK cell responses, even after tumor development, could be induced 
because the first immunization was administered before tumor development in the 
absence of immune suppression. However, exclusive therapeutic immunizations with 
Listeriaat-Mage-b were much less effective due to the strong immune suppression in the 
tumor microenvironment114. Cancer vaccination is highly promising, particularly against 
metastases, but a real breakthrough is hampered by the strong immune suppression in 
the tumor microenvironment. Therefore, reduction of immune suppression is of great 
value for the development of effective vaccines against cancer. This thesis is about the 
improvement of vaccine efficacy by the development of combination therapies with 
Listeriaat-Mage-b and curcumin or alphagalactosylceramide (#GC) against metastatic 
breast cancer. Both compounds reduce immune suppression and/or convert immune 
suppression into immune stimulation in tumor-bearing mice.  
 
Curcumin 
Curcumin (diferulolylmethane), a polyphenol derived from the plant Curcunina longa, 
commonly called turmeric, has a broad anti-cancer effect through down regulating 
transcription factor NFkB thereby affecting down stream genes such as c-myc, Bcl-2, 
COX-2, NOS, Cyclin D1, TNF# and MMP9 40. Various studies have shown that curcumin 
kills breast tumor cells in vitro117-121. Also it has been shown that curcumin improves 
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therapeutic efficacy of doxorubicin or of B16-R lysate against B16-R melanoma in 
mice122, and that curcumin prevents tumor-induced T cell apoptosis in mice123. Many 
clinical trials with curcumin are ongoing or have been completed (Table 3). Curcumin is 
also known for reducing immune suppressive cytokines such as IL-6 through the NFkB 
pathway124. IL-6 is strongly produced in mice and human with metastatic breast cancer, 
particularly in TNBC125,126. IL-6 is a potent regulator of dendritic cell (DC) differentiation in 
vivo127, and is able to turn on the expression of signal transducer and activator of 
transcription (STAT)3 in DC. However, high levels of STAT3 can prevent DC from 
maturation127 and subsequent presentation of antigens128. This in turn may lead to T cell 
unresponsiveness. In a previous study we found evidence that IL-6 strongly inhibited T 
cell responses in the TME and that anti-IL-6 antibodies restored the T cell responses113. 
We have also shown that IL-6 strongly inhibited T cell responses to Mage-b and that 
elimination of IL-6 with anti-IL-6 antibodies restored T cell responses to Mage-b113. 
Based on these results, we hypothesized that curcumin could improve the vaccine 
efficacy of Listeriaat-Mage-b by improving T cell responses through the reduced IL-6 
production. This hypothesis has been tested in Chapter 2.  
 
#-Galactosylceramide (#GC) 
#GC is a glycolipid and represents one potentially useful class of adjuvants that have 
shown promise in preclinical studies for immunotherapy of cancers129. These glycolipids 
mediate their effects on the immune system by binding to an MHC class I-like molecule 
called CD1d, creating a complex that is recognized by a population of conserved effector 
lymphocytes known as natural killer T cells (NKT cells)130. Several subsets of NKT cells 
have been defined, with the most abundant being the so-called type 1 or invariant NKT 
cell (iNKT) subset which is highly responsive to #GC and highly conserved between 
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primates and mice44,131. It has been shown that formation of complexes of CD1d with 
#GC intracellularly in antigen presenting cells initiates rapid NKT cell activation132. This 
cascade of immune reactions that is initiated by NKT cells in response to #GC has been 
shown in mouse models to generate innate and adaptive immunity against a wide range 
of cancers and infections132-136. Based on these observations we hypothesized that 
addition of #GC to the LM-Mb vaccine could improve the vaccine efficacy, in part 
through enhancement of specific T cell responses to Mage-b. This hypothesis has been 
tested in Chapter 3. 
 
Introduction to the experimental work 
Cancer vaccination is particularly promising to combat metastatic cancer. However, a 
real breakthrough is hampered by immune suppression in the TME. Therefore, the main 
goal of this thesis project is focused on the reduction or conversion of immune 
suppression in the TME. To reach this goal we have used two different approaches. The 
first approach involved reduction of immune suppressive cytokine IL-6. IL-6 strongly 
inhibits T cell responses in the TME, is a growth promoter for tumor cells, and 
contributes to the development of metastases. IL-6 is produced by at least 50% of all 
breast cancers (particularly stem-like breast cancer cells)137, and various immune cells in 
the TME (this thesis). We hypothesized that agents that reduce IL-6 will improve the 
efficacy of the vaccination through improved T cell responses. To test this hypothesis we 
developed a combination therapy of Listeriaat-Mage-b and Curcumin in a metastatic 
breast cancer model 4T1, in collaboration with Bharat Aggarwal, MD Anderson, 
Houston, Texas. This study has been described in Chapter 2.  
 The second approach involved the conversion of immune suppression into 
immune stimulation by generation of a cascade of immune-stimulating cytokines, 
 31 
through the activation of NKT cells with #GC. We hypothesized that the generation of 
immune-stimulating cytokines by #GC, will improve the efficacy of Listeriaat-Mage-b 
vaccinations through improved T cell responses to Mage-b. This hypothesis was tested, 
in collaboration with Dr. Steven Porcelli of Microbiology and Immunology of Albert 
Einstein College of Medicine, in chapter 3. 
 In summary, the various approaches to eliminate or convert immune suppression 
are of crucial importance for successful cancer vaccination. Another important issue was 
to develop non-toxic combination therapies. We have shown earlier that Listeriaat-Mage-
b is non-pathogenic and is naturally cleared by the immune system within 3-5 days114, 
and curcumin and #GC are both non-toxic compounds. Our ultimate goal is to apply our 
combination therapies in human clinical trials, with higher efficacy but lower side effects 
compared to current treatment regimens of metastatic breast cancer. 
 
 
1.! Chest wall 
2.! Pectoralis muscle 
3.! Lobules 
4.! Nipple 
5.! Areola 
6.! Milk duct 
7.! Fatty tissue 
8.! Skin 
Figure 1: Schematic view of breast tissue organization  
Source: http://www.who.int/cancer/detection/breastcancer/en/index2.html  
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Figure 2: Structure of the mammary gland. The mammary gland consists of a branching 
ductal system that ends in terminal ducts with their associated acinar structures, termed the 
terminal ductal-lobular units (TDLUs), together with interlobular fat and fibrous tissue. Terminal 
ductal–lobular unit (TDLU), composed of ductal cells, is the unit thought to be the origin of 
most breast cancers. The stroma is composed of fatty tissue (adipocytes) and fibroblasts. Also 
shown are the two primary types of cells in normal ducts: outer contractile myoepithelial and 
inner columnar luminal cells. A putative progenitor/stem cell is also indicated. 
Source: Dimri et al. Breast Cancer Research 2005 7:171   doi:10.1186/bcr1275 
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Figure 3: Venn diagram of breast cancer subtypes and their overlapping molecular 
targets. This figure shows some of the most promising targeted agents in development and 
discuss considerations for the optimal design of clinical trials of targeted therapies in breast 
cancer. The sub-classification nomenclature currently used in the clinic.  
Source: Higgins and Baselga, 2011, J Clin Inv 121: 3797-3803199 
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Figure 4: Immune recognition of tumours. The immune system can be broadly divided into innate and 
adaptive components, with extensive crosstalk between the two. The innate immune response functions as 
the first line of defense against infection. It consists of soluble factors, such as complement proteins, and 
diverse cellular components including granulocytes (basophils, eosinophils and neutrophils), mast cells, 
macrophages, dendritic cells and natural killer cells. The adaptive immune response is slower to develop, but 
manifests as increased antigenic specificity and memory. It consists of antibodies, B cells, and CD4+ and 
CD8+ T lymphocytes. Natural killer T cells and !"T cells are cytotoxic lymphocytes that straddle the interface of 
innate and adaptive immunity. 
Source: Dranoff. Cytokines in cancer pathogenesis and cancer therapy, Nature Reviews Cancer 4: 11-22, 
2004200 
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Figure 5A: Schematic of positive costimulatory pathways that could regulate specific stages in an anti-tumor 
immune response. Depicted are representations of the priming phase in secondary lymphoid organs, and the effector 
phase within the tumor microenvironment. Most costimulatory signals can be envisioned to improve aspects of the 
immune response in both compartments, to improve productive cross-priming by APCs, and to help maintain the 
desired functional properties of effector cell subsets. Specific receptor/ligand interactions are defined in the lower right 
section. APC, antigen-presenting cell; CTL, cytotoxic T lymphocyte. 
Source: Driessens et al. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunonol Rev, 229: 
126-144, 2009202 
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Figure 5B: Schematic of coinhibitory pathways that can be active within tumor-draining lymph nodes and 
the tumor microenvironment. Depicted are representations of the priming phase in secondary lymphoid organs, 
and the effector phase within the tumor microenvironment, along with key coinhibitory pathways that could dampen 
anti-tumor T-cell responses at each level. Several inhibitory signals, such as PD-L1/PD-1 interactions, can regulate 
both the effectiveness of tumor antigen cross-priming and the function of effector cells at tumor sites. Not all 
pathways are necessarily relevant to each subtype of cancer, nor do they necessarily coexist in all individual 
tumors. Specific receptor/ligand interactions are defined in the lower right section. PD, programmed cell death. 
Source: Driessens et al. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunonol Rev, 229: 
126-144, 2009202 
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Figure 6: The three Es of cancer immunoediting: elimination, equilibrium, and escape. (a) After 
transformation of cells in a normal layer (diamond-shaped cells) into cancerous cells (with irregular shapes), 
attack by various different cell types of the immune system (indicated by round cells) may lead to elimination of 
the cancerous cells. (b) If elimination is unsuccessful, the immune system and the cancer can reach an 
equilibrium in which immune cells keep the cancer in check but cannot remove it completely. During the 
elimination phase, there is selection on the cancer cells, whose genomes are also unstable. This can lead to 
escape (c), in which mutated cancer cells become able to inhibit the immune system. The cancer can then grow 
unchecked. Figure modified from [2]. CD4+, CD8+, CD4+CD25+ Treg, !" and NKT cells are all types of T cell; M# 
cells are macrophages and NK cells are natural killer cells. 
Strausberg. Tumor microenvironments, the immune system and cancer survival. Genome Biology 2005 6:211201 
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Table 1: List of most relevant TAAs recognized by T cells 
 
Shared Antigens    Type of Tumor   Normal tissue distribution  Ref 
 
Cancer Testis Antigens 
BAGE      melanoma, lymphoma,     spermatocytes, spermatogonia,  160-163 
GAGE       lung, bladder, colon,   testis, placenta, ovary cells 
MAGE-A/B      and breast carcinomas 
NY-ESO-1 
SSX 
 
Differentiation Antigens 
Gp100      melanoma, prostate cancer,  melanocytes, epithelial tissues,  164-166, 
Melan-A/Mart-1     colon and breast carcinomas  prostate, colon    167-171, 
Tyrosinase               185 
PSA 
CEA 
Mammaglobin-A 
 
Overexpressed Antigens 
P53      esophagus, liver, pancreas, colon ubiquitous (low level)    172-175 
HER2/neu     breast, ovary, bladder, and 
Livin      prostate carcinomas 
Survivin 
 
Unique Antigens 
Unique Antigens 
!-catenin-m     melanoma, non-small lung cancer, N/A      176-179 
!-actin/1/m     renal cancer 
Myosin/m 
HSP70-2/m 
HLA-A2-R170J 
 
Unique Shared Antigens 
Tumor-associated Carbohydrate Antigens 
GM2      melanoma, neuroblastoma,  epithelial tissues (e.g. renal, intestinal, 180-184 
GD2      colorectal, lung, breast, ovarian   colorectal) 
GD3      and prostate cancer 
MUC-1 
sTn 
globo-H 
 
Adapted from Buonaguro et al, 2011. Clin and Vacc Immunol 18: 23-24203 
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Table 2: Overview of different vaccination strategies employed in clinical trials 
 
VACCINE   PHASE   TUMOR  NOTE       REF 
Vaccines with vectors 
PSA-TRICOM   II   Prostate   8.5 mos OS improvement vs Placebo   186 
PSA-TRICOM   II   Prostate   16.4 mos OS improvement in HPS>18 mos   187 
PANVAC-VF   III   Pancreatic  Failed>OS. Pts with life expectancy < 3mos   188 
 
Vaccines with peptides 
Provenge   III   Prostate   4.1 mos improvement vs placebo    189,200  
Oncophage   III   Melanoma  Prolonged OS in M1a or M1b    191 
Gp100: 209-217 (210M)  III   Renal   No difference in DFS and OS    192 
Stimuvax   IIb   Lung   Improvement versus BSC in locoregional stage IIIB  193 
 
Vaccines with tumor cells or tumor cell lysates 
OncoVAX   III   Colon   Significant improvement in DFS and OS in stage II  194-196 
Reniale    III   Renal   Significant improvement in DFS and OS   197, 186 
GVAX    III   Prostate   Failed to improve OS vs docetaxel    188  
GVAX    III   Prostate   Failed. Higher death rate in vacc+doc vs doc alone  188 
 
Vaccines with RNA 
mRNA from PCa cell lines I/II   Prostate   Immunological response     198 
 
Vaccines with attenuated live bacteria1 
Listeria-E7   I/II   Cervix (invasive)  Flu-like symptoms; Detection of E7-specific T cell responses 103 
      
 
OS=overall survial; PFS= Progression-free survival; HPS=Halabi-predicted survival; DFS=disease-free survival 
Adapted from: from Vergati et al. J of Biomed Biotechnol 2010, doi:10.1155/2010/596432 (2010)186 
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Table 3: A list of most important completed, ongoing, and suspended clinical trials with curcumin in patients with different types of 
cancer 
 
Type of Cancer  Trial condition  Trial        Identifier No./Ref* 
 
Colon Cancer   Completed   The effects of curcuminoids on aberrant crypt foci   NCT00176618 
Colon Cancer   Completed   Curcumin in colon cancer      NCT00027495 
Colon Cancer   Ongoing (Phase II)  Curcumin in lower GI tract in FAP     NCT00248053 
Colon Cancer   Ongoing (Phase II)  Curcumin for chemoprevention colon cancer   NCT00118989 
Colon Cancer   Ongoing (Phase II)  Curcumin in colon cancer in smokers with aberrabant crypt foci NCT00365209 
Colon Cancer   Suspended   Curcumin effect on biomarkers of colon cancer cell turnover  NCT00003365 
Colon Cancer   Not yet open (Phase III)  Curcumin, gemcitabine, and celebrex in metastatic colon cancer NCT00542711 
Colon cancer   Suspended   Curcumin for intestinal FAP     NCT00641147 
 
Pancreatic Cancer  Ongoing (Phase II)  Curcumin in advanced pancreatic cancer    NCT00094445 
Pancreatic Cancer  Ongoing (Phase III)  Curcumin, gemcitabine, and celebrex in pancreatic cancer  NCT00486460 
Pancreatic Cancer  Ongoing (Phase II)  Curcumin with gemcitabine 
 
Oral Cancer   Ongoing (Phase II/III)  Oral premalignant lesions      See$ 
Oral Cancer   Ongoing (Phase II/III)  Oral premalignant lesions      See$ 
 
Cervical Cancer  Ongoing (Phase II/III)  Cervical cancer (stage IIb, IIIb)     See$ 
 
Gall bladder Cancer  Ongoing (Phase II)  Gall bladder Cancer      See$  
                  
Osteosarcoma   Ongoing    Curcumin and ashwaganda root powder extract    NCT00689195 
 
www.clinical trials.gov; $www.charakinternational.com/pdfs/clinic_trial.pdf. FAP= familial adenomatous polyposis 
Source: Shehzad et al, 2010, Arch Pharm Chem Life SCi 2010, 9, 489-499204 
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Abstract 
Success of cancer vaccination is strongly hampered by immune suppression in the tumor 
microenvironment (TME). Interleukin (IL)-6 is particularly and highly produced by triple negative 
breast cancer (TNBC) cells, and has been considered as an important contributor to immune 
suppression in the TME. Therefore, we hypothesized that IL-6 reduction may improve efficacy 
of vaccination against TNBC cancer through improved T cell responses. To prove this 
hypothesis, we investigated the effect of curcumin, an inhibitor of IL-6 production, on 
vaccination of a highly attenuated Listeria monocytogenes (Listeriaat), encoding tumor-
associated antigens (TAA) Mage-b in a TNBC model 4T1. Two therapeutic vaccination 
strategies with Listeriaat-Mage-b and curcumin were tested. The first immunization strategy 
involved all Listeriaat-Mage-b vaccinations and curcumin after tumor development. Since 
curcumin has been consumed all over the world, the second immunization strategy involved 
curcumin before and all therapeutic vaccinations with Listeriaat-Mage-b after tumor 
development. Here we demonstrate that curcumin significantly improves therapeutic efficacy of 
Listeriaat-Mage-b with both immunization strategies particularly against metastases in a TNBC 
model (4T1). The combination therapy was slightly but significantly more effective against the 
metastases when curcumin was administered before compared to after tumor development. 
With curcumin before tumor development in the combination therapy, the production of IL-6 
was significantly decreased and IL-12 increased by myeloid-derived suppressor cells (MDSC), 
in correlation with improved CD4 and CD8 T cell responses in blood. Our study suggests that 
curcumin improves the efficacy of Listeriaat-Mage-b vaccine against metastases in TNBC 
model 4T1 through reversal of tumor-induced immune suppression. 
 
Introduction 
Triple negative breast cancer (TNBC), defined as tumors lacking estrogen receptor (ER), 
progesterone receptor (PR), and HER2/neu accounts for about 20% of all breast cancers, and 
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is particularly increased in black women1. Women with TNBC represent high-grade tumors 
that are large and commonly associated with regional node metastases, and recur at distant 
sites, especially within the first 5 years of diagnosis2 . The absence of any specific targeted 
therapy for TNBC or basal subtype limits the therapeutic options to cytotoxic therapy3,4, 
indicating the need for new therapeutic approaches. Immunotherapy may be our best and 
most benign option for preventing or curing TNBC. However, immune suppression in the 
tumor microenvironment (TME) remains as a potential limitation to immunotherapy. Myeloid-
derived suppressor cells (MDSC) are one of the most important players in mediating TME-
associated immune suppression, with tumor-associated macrophages (TAM), Tregs, and M2 
macrophages also playing a role5-8. Interleukin (IL)-6 is one of such immune suppressive 
cytokines that is frequently and highly produced by metastatic breast cancers in humans and 
mice, and particularly by TNBC9-11. TNBC are enriched for stem-like breast cancer cells 
(CD44+/CD24-/low), which are typically aggressive and highly resistant to current therapies12-
15.  These stem-like breast cancer cells produce high levels of IL-6, and have the capacity to 
metastasize16. Moreover, IL-6 is capable of converting dormant breast cancer cells into an 
actively growing tumor. 
 IL-6 is a potent regulator of dendritic cell (DC) differentiation in vivo, and is able to turn on 
the expression of signal transducer and activator of transcription (STAT)3 in DC17. However, 
high levels of STAT3 can prevent DC from maturation and subsequent presentation of 
antigens18. This in turn may lead to T cell unresponsiveness. In a previous study we found 
high levels of IL-6 produced by breast cancer cells and by immune cells in their TME in an 
aggressive TNBC mouse model 4T119. This IL-6 strongly reduced T cell responses to Mage-b, 
but elimination of IL-6 using anti-IL-6 antibodies restored T cell responses to Mage-b in vitro20. 
 Agents that are able to inhibit IL-6 are of great value for immunotherapies against TNBC 
and other IL-6-producing cancers. One such agent could be curcumin. Curcumin 
(diferulolylmethane), a polyphenol derived from the plant Curcunina longa, commonly called 
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turmeric, has a broad anti-cancer effect through down regulating transcription factor NFkB 
thereby affecting down stream genes such as c-myc, Bcl-2, COX-2, NOS, Cyclin D1, TNF! 
and MMP9 21. Curcumin is also known for reducing immune suppressive cytokines such as IL-
6 through the NFkB pathway22. It has been shown that curcumin improves therapeutic efficacy 
of doxorubicin or of B16-R lysate against B16-R melanoma in mice, and that curcumin 
prevents tumor-induced T cell apoptosis in mice23. In a previous study we developed a 
Listeriaat-based vaccine expressing tumor-associated antigen (TAA) Mage-b20. Mage-b is 
homologous to Mage-a24, and its human homologue MAGE-A is expressed in 26% of the 
TNBC25. Vaccination with Listeriaat-Mage-b showed to be highly effective against metastatic 
breast cancer in a TNBC model 4T1 in a preventive setting20. However, Listeriaat-Mage-b was 
less effective in a therapeutic setting because of immune suppression in the TME. Here, we 
demonstrate that curcumin improved therapeutic efficacy of Listeriaat-Mage-b by reducing the 
production of IL-6 and increasing the production of IL-12, in correlation with improved T cell 
responses in blood of the TNBC 4T1 model. Most important, we found a dramatic effect of the 
combination therapy on the metastases without having side effects. The results of this study 
may provide new opportunities to improve efficacy of other types of vaccines and/or against 
other IL-6-producing cancers. 
 
 
Materials and Methods 
Mice.  
Normal female BALB/c mice (3 months old) were obtained from Charles River and maintained 
in the animal husbandry facility Albert Einstein College of Medicine according to the 
Association and Accreditation of Laboratory Animal Care (AACAC) guidelines. All mice were 
kept under Bsl-2 condition as required for Listeria vaccinations. 
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Cells and cell culture 
The  TNBC 4T1 cell line, derived from a spontaneous mammary carcinoma in a BALB/c 
mouse26, was cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 
10% fetal bovine serum (FBS), 1 mM mixed nonessential amino acids, 2 mM L-glutamine, 
insulin (0.5 HSP units/ml) penicillin (100 units/ml) and streptomycin (100 µg/ml).  
 
Listeriaat-based vaccine 
In this study, a highly attenuated Listeria monocytogenes (Listeriaat) has been used for the 
delivery of TAA Mage-b in vivo, as described previously20. The Listeriaat plasmid pGG-34, 
expresses the positive regulatory factor A (prfA) and one of the virulence genes Listeriolysin O 
(LLO)27. The coding region for the C-terminal part of the LLO (cytolytic domain that binds 
cholesterol in the membranes) protein in the plasmid has been deleted, but Listeriaat is still 
able to escape the vacuole28. Mutations have been introduced into the prfA gene and in the 
LLO, which further reduced the pathogenicity of the Listeriaat 27. The background strain XFL-7 
lacks the prFA gene, and retains the plasmid in vitro and in vivo28. Listeriaat-Mage-b, 
expressing nucleotide fragment 311-660 of mouse Mage-b, was developed earlier in our 
laboratory20. 
 
Curcumin 
As indicated in the text below, a dose of curcumin (95% curcuminoid)(Alfa Aesar, Ward Hill, 
MA) of 0.8 or 2 gram/kg (20 or 50 mg/mouse), in olive oil was administered orally. Piperine 
(black pepper) of 20 mg/kg (0.48 mg/mouse) was added to the olive oil in all studies with 
curcumin. Piperine improves the bioavailability with 2000%, and has been successfully used 
in humans and animals29. Piperine is a known inhibitor of hepatic and intestinal 
glucuronidation, a process that breaks down curcumin in vivo30,31. 
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Immunization and tumor challenge 
In this study, two different immunization protocols were tested. The first immunization protocol 
consisted of three therapeutic immunizations with Listeriaat-Mage-b and curcumin. Briefly, 
mice received 0.5x105 4T1 tumor cells in the mammary fat pad on day 0, then 0.5x107 CFU of 
Listeriaat-Mage-b, or Listeriaat or saline intraperitoneally (ip) on days 2, 9, and 16, and finally 
curcumin orally (50 mg curcumin + 0.48 mg black pepper in olive oil/mouse) on days 4, 5, 6, 
11,12, and 13 (Immunization protocol A). All mice were euthanized on day 17, and analyzed 
for the number of metastases and tumor growth. All untreated 4T1 mice developed a primary 
tumor that extended to the chest cavity lining and metastasized predominantly to the 
mesenteric lymph nodes (MLN), and less frequently to the diaphragm, portal liver, spleen, and 
kidneys within 14 days (metastases were visible as nodules and counted by eye) as described 
previously20 
 The second immunization protocol consisted of three therapeutic immunizations with 
Listeriaat-Mage-b, but curcumin was administered before tumor development. Briefly, mice 
received curcumin orally (50 mg curcumin + 0.48 mg black pepper in olive oil/mouse) on days 
0, 1 and 2, then 0.5x105 4T1 tumor cells in the mammary fat pad on day 5, and finally three 
therapeutic immunizations (ip) with 1x104 CFU Listeriaat-Mage-b, Listeriaat or saline on days 8, 
11 and 14 (Immunization protocol B). All mice were euthanized on day 16 and analyzed for 
metastases and tumor growth as described above.  
 
Flow cytometry analysis 
Cells were isolated from spleen and blood as described previously32. Briefly, red blood or 
spleen cells were lysed according standard protocols, and the remaining leukocyte population 
was used for analysis. Single cell suspensions were also obtained from primary tumors using 
GentleMacs combined with a mild treatment of the cells using Collagenase, Dispase, and 
DNAse I, according to the manufacturer’s instructions (Miltenyi, Biotec Inc, Auburn, CA).  
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 Cells were first incubated with an Fc blocker (anti-CD16), and subsequently with the 
antibodies for the identification of different cell types. For MDSC, anti CD11b and Gr1 
antibodies were used. CD11b+Gr1low represents monocytic MDSC (mMDSC), and 
CD11b+Gr1high granulocytic MDSC (gMDSC). Anti-CD8 antibodies were used to identify CD8 T 
cells and anti-CD4 to identify CD4 T cells. Anti-CD45 antibodies were used to identify the 
leukocyte population in the primary tumors. To detect the production of intracellular 
lymphokines the cytofix/cytoperm kit from Pharmingen according to the manufacturer’s 
instructions, and antibodies to IL-6, IL-12, and IFN", were used. Appropriate isotype controls 
were used for each sample. Depending on the sample size, 10,000-500,000 cells were 
acquired by scanning using a Fluorescence Activated Cell sorter (flow cytometry)(Beckton and 
Disckinson; Excalibur), and analyzed using Flojo software as described previously32. Cell 
debris and dead cells were excluded from the analysis based on scatter signals and use of 
Fixable Blue or Green Live/Dead Cell Stain Kit (Invitrogen). In blood and spleens, MDSC were 
analyzed in the total live gated leukocyte population, and T cells in the total live gated 
lymphocyte population. In the tumor cell suspension, MDSC and T cells were analyzed in the 
total live gated CD45+ (leukocyte) population. All antibodies were purchased from BD 
Biosciences Pharmingen. 
 
Cell proliferation, Mitotic Index, and Apoptosis 
Cell proliferation: 4T1 cells (2000 cells in 0.1 ml) were cultured with different doses of 
curcumin in dimethyl sulfoxide (DMSO) for 72 h, then cell viability was analyzed by 3-(4, 5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) method using a microtiter plate 
reader at a wave length of 570 nm. Mitotic Index: Sections of 1 mm thick of primary tumors of 
mice treated with Listeriaat-Mage-b and curcumin or with saline were stained with Hematoxylin 
and Eosin (H and E) and subsequently analyzed for the number of cells in mitosis by light 
microscopy. Apoptosis: Early and late apoptosis was analyzed by Annexin-V and TUNEL 
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assay, respectively. For the Annexin-V assay, 4T1 tumor cells were cultured with or without 
100 µM of curcumin for 24h, and subsequently incubated with Annexin-V antibodies (BD 
Biosciences), for the detection of apoptosis. For the TUNEL Assay, the ApoTag® In Situ 
Apoptosis detection (Millipore) was used. Briefly, slides were deparaffinized through graded 
alcohols to PBS. TUNEL staining was performed using ApopTag® In Situ Apoptosis Detection 
Kit (Millipore). Briefly, samples were Proteinase K digested (20 !g/mL) for 15 minutes at room 
temperature. Endogenous peroxidases were blocked using 3% H2O2 for 5 minutes at RT. 
Samples were washed and placed in Equilibration Buffer for 10 seconds followed by TdT 
enzyme incubation in reaction buffer for 1 hr at 37°C. Samples were incubated in the Anti-
Digoxigenin, washed and developed using DAB (3,3' diaminobenzidine). Slides were briefly 
counterstained in hematoxylin and mounted using Permount (Fisher Scientific). From each 
tissue, two sections were analyzed, and from each section the number of apoptotic cells in 10 
fields were counted by light microscopy. The TUNEL assay and Mitotic Index analyses were 
performed in the Laboratory of Dr. Rani Sellers, Director of Histology and Comparative 
Pathology Core Facility, Albert Einstein College of Medicine. 
 
Pathological examination 
All pathological analyses were performed by Dr. Rani Sellers, Director of Histology and 
Comparative Pathology Core Facility, Albert Einstein College of Medicine. Briefly, normal 
tissues such as kidneys, heart, lungs, liver and spleen were fixed in 10% formaldehyde for 48 
hrs, and then kept in 70% ethanol until use. Sections of 1 mm thick were stained with H and E, 
and analyzed for pathological damage by light microscopy. 
 
Results 
Curcumin administered after tumor development significantly improved therapeutic 
effect of Listeriaat-Mage-b in the 4T1 model 
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Here we tested whether curcumin could improve the efficacy of Listeriaat-Mage-b vaccination 
in the model 4T1. Listeriaat-Mage-b and curcumin were alternately administered after tumor 
development (Immunization protocol A). As shown in Fig 1A, the number of metastases in the 
mice that received Listeriaat-Mage-b and curcumin was significantly lower compared to all 
control groups. Also the tumor weight in the mice that received Listeriaat-Mage-b and curcumin 
was significantly lower than in the mice that received Listeriaat or curcumin alone, but not 
compared to the mice that received Listeriaat-Mage-b alone (Fig 1B). Curcumin alone had no 
significant effect on the tumor weight compared to the saline group. 
 
Curcumin administered before tumor development also significantly improved 
therapeutic effect of Listeriaat-Mage-b in the 4T1 model 
Since curcumin is frequently used in food all over the world we tested whether curcumin could 
improve therapeutic vaccine efficacy of Listeriaat-Mage-b when consumed before tumor 
development (Immunization protocol B). Here we used a low dose of Listeriaat-Mage-b (104 
CFU) at a high frequency (every 3 days; 4 times totally) in order to obtain a continuous 
delivery of Listeriaat-Mage-b in vivo without having side effects. Using this immunization 
protocol, the number of metastases in the mice that received Listeriaat-Mage-b and curcumin 
was significantly decreased compared to all control groups (Fig 2A). Also the tumor weight in 
the mice that received Listeriaat-Mage-b and curcumin was significantly lower compared to all 
control groups (Fig 2B). Curcumin alone had also a significant effect on the metastases and 
primary tumors compared to the saline group (Fig 2B). The growth kinetics of the primary 
tumors was analyzed as well in mice that received Listeriaat-Mage-b and curcumin, and 
confirmed the results shown in Fig 2B, i.e. on day 14 the tumor size in mice that received 
Listeriaat-Mage-b and curcumin was significantly lower compared to all other control groups 
(Supplementary Information Fig S1). 
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 The combination therapy with curcumin before and Listeriaat-Mage-b after tumor 
development was slightly but significantly more effective against the metastases than 
curcumin and Listeriaat-Mage-b both after tumor development (Figs 2AB and 3AB), i.e. the 
number of metastases in the combination therapy with curcumin before tumor development 
was 4±1, and after tumor development 31±12 (Mann-Whitney p=0.0017).  
 
The effects of Listeriaat-Mage-b and curcumin on MDSC in vivo 
Since MDSC strongly contributes to immune suppression in the TME, we analyzed the effect 
of the combination therapy on MDSC in blood and primary tumors of mice immunized 
according to immunization protocol B. In total blood, the percentage of MDSC was extremely 
high (#80%)(Fig 3A). This percentage was strongly reduced to #20% by the combination of 
Listeriaat-Mage-b and curcumin compared to the saline group, but was also significantly lower 
compared to all other control groups (Fig 3A). More detailed analysis showed that 
granulocytic (g)MDSC was predominantly responsible for the strong decrease in percentage 
of MDSC (Fig 3BC). In the primary tumors, the percentage of MDSC (in CD45+ population) 
was much lower than in blood (#12%), and the effect of Listeriaat-Mage-b and curcumin on 
MDSC was much less robust than in blood. The combination therapy slightly but significantly 
reduced the percentage of MDSC and gMDSC (but not of monocytic (m)MDSC) compared to 
the saline or curcumin groups only (Fig 3DEF).  
 
Curcumin reduced the production of IL-6 in primary tumors and in MDSC 
Here, we analyzed the effect of curcumin on the production of IL-6 in total tumor cell lysates, 
in MDSC of primary tumors and blood, and in serum of the 4T1 model. In the tumor cell 
lysates (Fig 4A) and in mMDSC and gMDSC of the primary tumors (Fig 4BC) we found that 
curcumin significantly reduced IL-6 levels compared to the control groups. In blood, IL-6 was 
significantly reduced by curcumin in mMDSC compared to the Listeriaat-Mage-b group (Fig 
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4E), but IL-6 was not produced by gMDSC. In serum, IL-6 was undetectable and therefore not 
shown 
 Also Listeriaat-Mage-b reduced IL-6 levels in the primary tumors (tumor cell lysates) (Fig 
4A), but not in MDSC in blood and primary tumors (Fig 4B-C). Moreover, Listeriaat-Mage-b 
significantly increased the production of IL-6 in sub populations of the MDSC (with an 
exception of gMDSC in tumors), probably to protect them selves from immune clearance, but 
as mentioned above curcumin strongly reduced the IL-6 production in both types of MDSC in 
blood (Fig 4DE).  
 
Curcumin administered before and Listeriaat-Mage-b after tumor development improved 
the IL-12 production by MDSC and T cell responses to Mage-b 
Here we analyzed the IL-12 production in subpopulations of gMDSC and mMDSC in blood of 
mice that received the combination of curcumin before and Listeriaat-Mage-b after tumor 
development. A significant increase was found in the percentage of IL-12-producing gMDSC 
and mMDSC in the combination group compared to all other groups (Fig 5AB), but not in the 
primary tumor (data not shown). These results raised the question whether the lower number 
of MDSC (Fig 3), the decreased IL-6 levels (Fig 4) and increased IL-12 production (Fig 5AB) 
induced by Listeriaat-Mage-b and curcumin, could improve T cell responses in vivo. For this 
purpose, we analyzed the production of IFN" by CD4 and CD8 T cells in blood and primary 
tumors in vaccinated and control mice by flow cytometry. IFN" is a marker for T cell activation. 
The cells were analyzed in all groups without re-stimulation in order to determine whether the 
T cells were activated in vivo by the combination therapy compared to the control groups. It 
appeared that the combination of Listeriaat-Mage-b and curcumin significantly improved the 
percentage of CD4 and CD8 T cells producing intracellular IFN" compared to all control 
groups in blood (Fig 5CD), but not in tumors (data not shown). We also analyzed T cells 
responses in the spleen upon re-stimulation with Mage-b in vitro. As shown in Fig 5E, 
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Listeriaat-Mage-b and curcumin strongly improved the number of CD8 T cells to Mage-b, 
secreting extracellular IFN".  
 
Curcumin inhibited proliferation of tumor cells and killed tumor cells through apoptosis 
Several reports describe that curcumin inhibits proliferation and kills tumor cells through 
apoptosis, including breast tumor cells33-35. We found that curcumin inhibited the growth of 
4T1 tumor cells in vitro (Fig 6A), and mitosis of the tumor cells in vivo (Fig 6B). In addition, we 
found that curcumin killed tumor cells through apoptosis in vitro as shown by Annexin-V (early 
apoptosis) (Fig 6C), and in the primary tumors in vivo as shown by the TUNEL assay (late 
apoptosis) (Fig 6D). A representative example of apoptotic cells by the TUNEL assay is 
shown by light microscopy in Fig 6E.  
 
Listeriaat-Mage-b is non-pathogenic and curcumin is non-toxic 
In a previous study we have shown that Listeriaat-Mage-b is non-pathogenic20, while curcumin, 
consumed through food all over the world, is non-toxic31. However, the combination of 
Listeriaat-Mage-b and curcumin has never been tested. Here, we demonstrate by pathological 
examination of various normal tissues (as kidney, heart, lungs, liver, and spleen) in tumor-
bearing mice that the combination of Listeriaat-Mage-b and curcumin is non-pathogenic and 
non-toxic, but primarily activated the innate immune system. Most obvious was the increased 
extramedullary myeloid hematopoiesis in the spleen and liver of mice that received Listeriaat-
Mage-b and curcumin compared to the saline group. An example of extramedullary myeloid 
hematopoiesis in the liver is shown in the Supplementary Information Fig S2. An overview 
of pathological analysis of normal tissues of tumor-bearing mice that received Listeriaat-Mage-
b and curcumin is shown in Table S1 of the Supplementary Information.  
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Discussion 
Patients with TNBC have the poorest prognosis. One of the main problems of current 
therapies against TNBC is their inability to target metastases and their high toxicity. They do 
not respond to therapies that target ER, PR, and HER2/neu because their tumors lack the 
expression of these receptors/molecules, and other types of therapies such as tyrosine kinase 
inhibitor Sunitinib, targeting vascular endothelial growth factor (VEGF), or therapies targeting 
c-kit or Flt2, or Bevacizumab, a human antibody to VGEF36-40, are under investigation but with 
moderate success. In the study presented here, we developed two non-toxic vaccination 
strategies in a preclinical TNBC mouse model 4T1. We demonstrated that three therapeutic 
vaccinations with a highly attenuated non-pathogenic Listeriaat-based vaccine, expressing 
TAA Mage-b, and non-toxic curcumin significantly reduced the number of metastases 
compared to Listeriaat-Mage-b or curcumin alone. However, curcumin alone had no significant 
effect on the primary tumors and metastases. Others described that curcumin killed tumor 
cells41-45. These studies were all performed in vitro, while we analyzed the effect of curcumin 
on the primary tumor and metastases in vivo, which may be an explanation for the different 
results. Different types of tumor cells, concentrations and time points of curcumin 
administration may lead to different results as well46. 
 We also tested three administrations of curcumin before tumor development followed by 
three immunizations with Listeriaat-Mage-b after tumor development. This immunization 
protocol was slightly but significantly more effective against the metastases compared to 
Listeriaat-Mage-b and curcumin both after tumor development. Most interestingly, curcumin 
alone significantly reduced the number of metastases and tumor growth, in contrast to 
administering curcumin after tumor development. These results suggest that consuming 
curcumin before cancer develops may provide an advantage over consuming curcumin after 
cancer develops in the battle against metastatic breast cancer. 
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 Curcumin is known for reducing the production of IL-647,48. Here we demonstrate that 
curcumin significantly reduced the production of IL-6 in vivo in the primary tumors (tumor cell 
lysates), and in MDSC of blood and primary tumors. Also Listeriaat-Mage-b reduced the 
production of IL-6 significantly, but this reduction was stronger by the combination of Listeriaat-
Mage-b and curcumin. 
 MDSC are important regulators of the immune system in the TME5,6, and therefore 
became one of our most important targets in this study. As mentioned above, curcumin 
reduced the production of IL-6 significantly in MDSC in blood and primary tumors. To our 
surprise, the combination of Listeriaat-Mage-b and curcumin significantly increased the 
production of IL-12 in gMDSC and mMDSC in blood (but not in tumors). It has been reported 
that IL-12 activates naïve and mature CD4 and CD8 T cells49,50, which may have happened in 
this study as well. An interesting observation was that the combination of Listeriaat-Mage-b 
and curcumin significantly reduced the number of MDSC (predominantly gMDSC) in blood of 
the TNBC model 4T1. It is possible that MDCS infected with Listeriaat-Mage-b became a target 
for Listeriaat- and Mage-b-specific T cell and perhaps NK cell responses because the 
combination therapy improved these immune responses to Listeriaat and Mage-b by reducing 
IL-6, and increasing IL-12 production. Since Listeriaat51 and curcumin kill 4T1 tumor cells 
directly (this study), it is also possible that the combination therapy prevented the tumor cells 
from growing in the early phase of treatment, and consequently prevented migration of the 
MDSC to the TME. We found that curcumin alone decreased the percentage of MDSC in 
blood (although this effect was much stronger when Listeriaat-Mage-b was combined with 
curcumin). Reduction in the percentage of MDSC by curcumin was also found by others in a 
xenograft model of colon cancer52. They concluded that reduction in IL-6 production by 
curcumin reduced the mobilization of MDSC to the primary tumors. Others found that 
activated T cells might express Fas ligand and induce apoptosis of Fas+ MDSC53. In 
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conclusion, various pathways may lead to the reduction in MDSC and more analysis is 
required. 
  The decrease in IL-6 and increase in IL-12 production, the improved CD4 and CD8 T 
cell responses in blood and spleen, and the dramatic reduction in the number of metastases 
by the combination therapy strongly suggest that T cell responses contributed to the effect on 
the metastases. However, this strong reduction by the combination therapy is not only an 
effect of Mage-b-specific immune responses. As shown previously, Listeriaat exhibits several 
pathways to kill tumor cells, i.e. Listeriaat infects tumor cells in vivo and in vitro, and kills tumor 
cells directly through high levels of reactive oxygen species (ROS)51. Moreover, we have 
shown that Listeriaat-activated CD8 T cells eliminated Listeriaat-infected tumor cells in vivo51. In 
addition, we have shown that curcumin kills 4T1 tumor cells through apoptosis (this study). 
Therefore, it is most likely that the synergistic effects of the multiple pathways of Listeriaat-
Mage-b and curcumin as described above, are responsible for the overall strong therapeutic 
effect on the metastases in this TNBC model 4T1.  
 The therapeutic effect of the combination therapy was strong but less pronounced on the 
primary tumors compared to the metastases. It is possible that the production of IL-6 was not 
sufficiently reduced in the primary tumors (IL-6 was reduced in the tumor cell lysates by #65% 
by Listeriaat-Mage-b and curcumin treatment), and another inhibitory cytokine such as TGF$, 
which is highly produced by 4T1 tumor cells54, may play a role as well. However, most primary 
tumors can be removed by surgery, radiation or chemotherapy, while metastases are 
unresectable, and usually chemoresistant despite aggressive and toxic follow-up55.  
 The highly attenuated Listeriaat of this study is non-pathogenic, and naturally cleared by 
the immune system within 3-5 days51, which is different from wild type Listeriaat that multiplies 
in hepatocytes in the liver or epithelial cells of the gastrointestinal tract56,57. Moreover, the side 
effects of the combination therapy of Listeriaat-Mage-b and curcumin in the 4T1 model were 
minimal, i.e. primarily induction of inflammatory responses in the liver and spleen and no 
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significant findings were observed in other normal tissues such as heart, lungs and kidneys. 
Therefore, Listeriaat-Mage-b and curcumin may be of value as a non-toxic adjuvant therapy, to 
prevent the development of metastases in TNBC patients that produce IL-6 and express 
MAGE. This study may be a platform for improvement of other cancer vaccines by curcumin 
and against other IL-6-producing cancers. 
 
 
Acknowledgments 
This work was supported by NCI grant 1R21CA129470-01A1 and NIA/NCI grant 1RO1 
AG023096-01. We like to thank Lydie Tesfa of the FACS Facility Core of Einstein and Lisa 
Scandiuzzi of Dr. Xingxing Zang’s laboratory for their excellent assistance with the flow 
cytometry.  
 
 
Legends 
Figure 1: Significant reduction in the number of metastases by therapeutic 
immunizations with Listeriaat-Mage-b and curcumin in 4T1 tumor-bearing mice. BALB/c 
mice were immunized with Listeriaat-Mage-b and treated with curcumin after tumor 
development (Immunization protocol A), and analyzed for the frequency of metastases (A) 
and tumor weight (B). This experiment was performed two times with 5 mice per group. 
Average of two experiments. Mann-Whitney p<0.05 is significant. * p<0.05, **<0.01, 
***<0.001, ****<0.0001. ns=not significant. All groups were compared to LM-Mb+Curc. In 
addition, curcumin alone was compared to the saline group.  
 
Figure 2: Significant reduction in the number of metastases by preventive 
administration of curcumin followed by therapeutic immunization with Listeriaat-Mage-b 
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in 4T1 tumor-bearing mice. BALB/c mice were treated with curcumin before tumor 
development and immunized with Listeriaat-Mage-b after tumor development (Immunization 
protocol B), and analyzed for the frequency of metastases (A), tumor weight (B). This 
experiment was performed three times with 5 mice per group. Average of three experiments. 
Mann-Whitney p<0.05 is significant. * p<0.05, **<0.01, ***<0.001, ****<0.0001. ns=not 
significant. All groups were compared to LM-Mb+Curc. In addition, curcumin alone was 
compared to the saline group.  
 
Figure 3: The effect of Listeriaat-Mage-b and curcumin on MDSC in 4T1 tumor-bearing 
mice. BALB/c mice were treated with curcumin before tumor development and immunized 
with Listeriaat-Mage-b after tumor development (Immunization protocol B), and analyzed for 
MDSC (CD11b+Gr1+)(A), gMDSC (CD11b+Gr1high)(B), and mMDSC (CD11b+Gr1low) (C) in 
blood and for MDSC (D), gMDSC (E), and mMDSC (F) in primary tumors using flow 
cytometry. All groups were compared to Lm-Mb+Curc. Flow cytometry profiles of MDSC of 
each group (saline, Listeriaat, Listeriaat-Mage-b, Listeriaat-Mage-b and curcumin, curcumin) are 
presented in the Supplementary Information Fig S3. This experiment was performed three 
times with 5 mice per group. Average of 3 experiments. Mann-Whitney p<0.05 is significant. 
*p<0.05, **<0.01, ***<0.001, ****<0.0001. ns=not significant.  
 
Figure 4: Effects of Listeriaat-Mage-b and curcumin on IL-6 in 4T1 tumor-bearing mice. 
Curcumin treatment before tumor development followed by immunizations with Listeriaat-
Mage-b after tumor development (Immunization protocol B), significantly reduced IL-6 levels in 
primary tumors as shown here by ELISA (A), and the intracellular production of IL-6 by 
gMDSC and mMDSC in primary tumors (BC) and by mMDSC in blood (DE) as shown here by 
flow cytometry. In A, the curcumin-containing groups were compare to the saline group, while 
in BC and ED, the curcumin-containing groups were compared to Lm-Mb. These experiments 
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were repeated three times with 5 mice per group, and the results were averaged. Mann-
Withney p<0.05 is significant. Mann-Whitney p<0.05 is significant  *p<0.05, **<0.01, 
***<0.001, ****<0.0001. ns=not significant.  
 
Figure 5: The combination of Listeriaat-Mage-b and curcumin increased IL-12 
production by MDSC and improved T cell responses in 4T1 tumor-bearing mice. 
Curcumin treatment before tumor development followed by immunizations with Listeriaat-
Mage-b after tumor development (Immunization protocol B) significantly increased the 
percentage of gMDSC (A) and mMDSC (B) producing intracellular IL-12 in blood of 4T1 
tumor-bearing mice. This correlated with a significant increase in the percentage of CD4 (C) 
and CD8 T (D) cells producing intracellular IFN" (activation marker for T cells) in blood of 4T1-
tumor-bearing mice as shown here by flow cytometry. CD8 T cell responses (extracellular 
production of IFN") were also analyzed in the spleen in vitro upon re-stimulation with Mage-b 
by ELISPOT, and a significant higher number of CD8 T cells was found in the spleen that 
received Listeriaat-Mage-b and curcumin compared to all other groups (E). These experiments 
were repeated three times with 5 mice per group, and the results were averaged. Mann-
Whitney p<0.05 is significant. * p<0.05, **<0.01, ***<0.001, ****<0.0001.  
 
Figure 6: Curcumin inhibited proliferation and killed 4T1 tumor cells through apoptosis. 
4T1 tumor cells were cultured with different doses of curcumin for 72 h, and cell viability was 
analyzed by MTT (A). We also analyzed the Mitotic Index in tumors of mice that received 
curcumin or saline (B). 4T1 tumor cells were cultured with 100 µM of curcumin in vitro for 24h, 
and subsequently incubated with anti-Annexin-V antibodies for the detection of early 
apoptosis (C). Primary tumors of mice that received curcumin or saline (according 
Immunization protocol B) were analyzed for the detection of late apoptosis in vivo by the 
TUNEL assay (D). Apoptotic cells in the primary tumor by the TUNEL assay and light 
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microscopy are shown in (E). Representative of two experiments in A, C, D. Average of two 
experiments in B and D. n= 5 mice per group. Unpaired t test p<0.05 is significant. 
Magnification light microscopy in C and E is 400x. In A, curcumin was dissolved in DMSO and 
then diluted to the final concentrations of 1-50 uM. The 0 µM represents DMSO without 
curcumin. 
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Legends  
Figure S1: Significant reduction in the tumor size by preventive administration of 
curcumin followed by therapeutic immunization with Listeriaat-Mage-b in 4T1 
tumor-bearing mice. BALB/c mice were treated with curcumin before tumor 
development and immunized with Listeriaat-Mage-b after tumor development 
(Immunization protocol B), and analyzed for tumor weight during the treatments. This 
experiment was performed two times with 5 mice per group, and the results were 
averaged.  
 
Figure S2: The combination therapy of Listeriaat-Mage-b and Curcumin is non-
pathogenic and non-toxic. BALB/c mice were treated with Curcumin before tumor 
development and immunized with Listeriaat-Mage-b after tumor development 
(Immunization protocol B). Two days after the last immunization, mice were euthanized 
and liver sections were stained by H&E, followed by pathological examination. 
Extramedullary hematopoiesis (black arrow) was mild and multifocal in the liver (possibly 
tumor related) of both groups, i.e. Saline (negative control) and Listeriaat-Mage-b and 
Curcumin. There were also scattered infiltrates of immune cells (incidental background 
finding) found in the liver of both groups of mice. The boxed areas in the top 
(magnification 200x) are shown in a larger magnification at the bottom (Light microscopy 
Magnification: 600x). Representative of two experiments. 
 
Figure S3: The effect of Listeriaat-Mage-b and Curcumin on MDSC in 4T1 tumor-
bearing mice (Flow cytometry profile). BALB/c mice were treated with Curcumin 
before tumor development and immunized with Listeriaat-Mage-b after tumor 
development (Immunization protocol B), and analyzed for MDSC (CD11b+Gr1+)(A), 
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gMDSC (CD11b+Gr1high)(B), and mMDSC (CD11b+Gr1low) (C) in blood and for MDSC 
(D), gMDSC (E), and mMDSC (F) in primary tumors using flow cytometry. 
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Table S1: Histological examination of tissues after therapeutic treatment with  
Listeria-Mage-b and curcumin 
 
      Mouse number                 Mouse number 
 
Organ  S1 S2 S3 S4 S5  MC1 MC2 MC3 MC4 MC5 
 
Kidney  nsf nsf nsf nsf nsf  nsf nsf nsf nsf nsf 
 
Heart  nsf nsf nsf nsf nsf  nsf nsf nsf nsf nsf 
 
Lung  icn3 icn1 icn2 icn3 icn1  icn3 icn3 icn1 icn3 icn3 
 
Liver  cn0 cn0 cn0 cn0 cn0  cn1 cn0 cn0 cn0 cn0 
 
Liver  emh3 emh0 emh2 emh3 emh1  emh4 emh4 emh1 emh2 emh3 
 
Liver  ipp1 ipp0 ipp1 ipp1 ipp0  ipp2 ipp2 ipp0 ipp1 ipp2 
 
Liver  gmi1 gmi0 gmi1 gmi1 gmi1  gmi2 gmi3 gmi0 gmi1 gmi0 
 
Spleen  imh2 imh1 imh2 imh3 imh1  imh3-4 imh3-4 imh0 imh4 imh3-4 
 
Nsf=no-significant finding, icn=increased circulating neutrophils, cn=coagulation necrosis,  
emh=extramedullary hematopoiesis, ipp=infiltrate, portal, mixed polymorphonuclear cells,  
gmi=granulomas, mixed inflammation, imh=increased myeloid extramedullary hematopoiesis 
The numbers after the abbreviations represents the grade. 0=no finding, 1=minimal finding, 2= mild  
finding, 3=moderate finding, 4=marked finding, 5=severe finding. S=saline, MC=Listeria
at
-Mage-b and  
curcumin. 
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Abstract 
  
Introduction: Immune suppression in the tumor microenvironment (TME) remains a 
major limitation to successful immunotherapy of cancer, and a major focus of cancer 
research is the discovery of new adjuvants and vaccine regimens that overcome this 
suppression.  In the current study, we developed a combination immunotherapy using an 
attenuated Listeria monocytogenes-based vaccine expressing the tumor-associated 
antigen (TAA) melanoma-associated antigen (Mage)-b (LM-Mb) and the natural killer T 
(NKT) cell-activating glycolipid !-galactosylceramide (!GC).  This glycolipid has been 
previously identified as a potent immunological adjuvant because its ability to stimulate 
CD1d-restricted NKT cells, which drives a cascade of immune reactions that include 
potent stimulation of natural killer (NK) cell effector functions and cross-priming of 
antigen specific CD8+ T cells.  
Methods: Mice with metastatic breast cancer (4T1 model) were therapeutically treated 
with LM-Mb and !GC (3 immunizations) as separate agents or as a complex of !GC 
stably incorporated into Lm-Mb (5 immunizations).  Two days after the last treatment, the 
mice were analyzed for the number of metastases, tumor weight, toxicity, and immune 
responses. 
Results: We found that sequential treatments of mice with established 4T1 breast 
carcinomas using LM-Mb followed by !GC was highly effective at reducing metastases, 
but was accompanied by severe liver toxicity. In contrast, the simultaneous 
administration of these two agents, using a method to stably incorporate !GC into the 
live LM-Mb organisms, resulted in a therapeutic vaccine that reduced the metastases by 
more than 99% without evidence of toxicity.  The anti-metastatic response in mice 
immunized with LM-Mb incorporated with !GC was associated with a significant 
increase in IL-12 production, increased NK cell activity and an increase in T cell 
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responses to Mage-b.  This combination therapy did not result in depletion or anergy of 
NKT cells, which has been repeatedly identified as a problem resulting from treatment of 
mice with !GC alone.   
Conclusions: These results define a highly promising new approach for combining two 
immunotherapeutic agents in one complex of Lm-Mb and !GC to create an efficacious 
and non-toxic vaccine regimen for prevention of metastatic breast cancer. 
 
 
Introduction 
Breast cancer is the most common cancer among women world-wide [1], and 30% of 
women diagnosed with breast cancer will progress to metastatic disease which is difficult 
or impossible to treat effectively [2].  Current treatment options for metastatic cancer 
include surgery followed by chemotherapy or radiation, or other adjuvant therapy [3]. 
Despite aggressive treatment, for most patients the elimination of metastases or residual 
tumor cells after initial treatment is incomplete, and removal of residual disease by 
chemotherapy is prevented by chemoresistance [4].  Thus, metastases and not the 
primary tumor is the most important contributor to breast cancer morbidity and mortality. 
It has been shown in mice and humans that vaccines can have a favorable effect 
on metastases [5],[6],[7],[8],[9],[10],[11], but that vaccine efficacy is strongly reduced by 
immune suppression in the tumor microenvironment (TME) [12].  In a previous study, we 
developed a vaccine based on a non-pathogenic strain of Listeria monocytogenes (LM) 
for the delivery of the tumor-associated antigen (TAA) Mage-b (LM-Mb) in vivo, (11).  LM 
is an intracellular bacterium which has the capacity to deliver antigens through infection 
into antigen-presenting cells (APC) such as dendritic cells (DC), monocytes and 
macrophages with high efficiency [13].  We have also demonstrated that LM infects 
tumor cells, which can lead to cytolytic effects through a mechanism involving induction 
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of high levels of reactive oxygen species (ROS), and sensitizes the infected tumor cells 
for recognition by LM-specific CD8+ T cells [14].  When administered prior to tumor 
establishment in an aggressive mouse model of metastatic breast cancer (4T1), LM-Mb 
treatment resulted in strong CD8+ T cell responses to both Mage-b and LM and an 
almost complete elimination of metastatic disease [11].  However, when administered in 
a therapeutic immunization regimen (i.e., after establishment of primary 4T1 tumors), 
LM-Mb treatment was only moderately effective against metastatic breast cancer, and 
induced relatively weak CD8+ T cell responses to Mage-b [14].  This failure to stimulate 
adequate CD8+ T cell responses in tumor-bearing hosts is indicative of the chronic 
immunosuppression associated with the TME, and represents a major problem in cancer 
vaccination. 
To overcome the immune suppression that is characteristic of tumor-bearing 
hosts, there is an urgent need for development of immunologic adjuvants that can 
promote robust immune responses in this setting and augment the effects of therapeutic 
vaccines.  Glycolipids of the !-galactosylceramide family (!GC) represent one 
potentially useful class of adjuvants that have shown promise in preclinical studies for 
immunotherapy of cancers [15].  These glycolipids mediate their effects on the immune 
system by binding to an MHC class I-like molecule called CD1d, creating a complex that 
is recognized by a population of conserved effector lymphocytes known as natural killer 
T cells (NKT cells) [16],[17].  Several subsets of NKT cells have been defined, with the 
most abundant being the so-called type 1 or invariant NKT cell (iNKT) subset which is 
highly responsive to !GC and highly conserved between primates and mice [18],[19].  It 
has been shown that formation of intracellular complexes of CD1d with !GC in antigen 
presenting cells initiates rapid NKT cell activation [20], resulting in the production of Th1-
associated cytokines such as IFN" and IL-12p70, maturation of the CD8!+ DCs in the 
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lymph nodes and subsequent activation of NK and conventional T cells [17].  This 
cascade of immune reactions that is initiated by NKT cells in response to !GC has been 
shown in mouse models to generate innate and adaptive immunity against a wide range 
of cancers and infections [21],[22],[23],[20],[24].  Based on these observations we 
hypothesized that addition of !GC to the LM-Mb vaccine could improve the vaccine 
efficacy, in part through enhancement of specific T cell responses to Mage-b.  
 Here, we developed a therapeutic immunization protocol for the combination of 
LM-Mb and !GC, and developed a safe and effective method for delivering this 
immunotherapy to tumor bearing mice.  When these two agents were used as 
combination therapy in the 4T1 model, !GC significantly improved the therapeutic 
vaccine efficacy of LM-Mb as demonstrated by the almost complete elimination of the 
metastases. However, the administration of these two agents sequentially, using a 
series of LM-Mb injections followed by a series of systemic !GC injections, caused 
severe and in some cases fatal toxicity to the liver. Therefore, we explored other novel 
strategies to improve the vaccine efficacy of Lm-Mb but at lower dose of !GC. Drawing 
on previous experience using direct incorporation of relatively low doses of !GC into live 
Mycobacterium bovis BCG to improve vaccine efficacy [25], we developed a similar 
approach for direct incorporation of the glycolipid into live LM organisms.  Therapeutic 
immunizations with !GC directly incorporated into live LM-Mb was equally effective 
against the metastatic breast cancer compared to sequential administration of LM-Mb 
and !GC as separate agents, but without any apparent toxicity.  The powerful anti-
metastatic effect of vaccination with LM-Mb modified by direct incorporation of !GC 
correlated with increased IL-12 production and improved Mage-b-specific CD8+ T cell 
and NK responses. This novel approach using incorporation of !GC into live LM may 
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provide a basis for new strategies to improve vaccine efficacy against metastatic cancer 
through augmentation of multiple innate and adaptive immune mechanisms. 
 
Materials and Methods 
Mice 
Normal 3 month old female BALB/c mice were obtained from Charles River Laboratories 
and maintained in the animal husbandry facility at Albert Einstein College of Medicine 
according to the Association and Accreditation of Laboratory Animal Care (AALAC) 
guidelines. All mice were kept under biosafety level 2 conditions as required for LM 
vaccinations. 
 
Cells and cell culture 
The TNBC 4T1 cell line, derived from a spontaneous mammary carcinoma in a BALB/c 
mouse [26], was cultured in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 1 mM mixed nonessential amino 
acids, 2 mM L-glutamine, insulin (0.5 USP units/ml), penicillin (100 units/ml) and 
streptomycin (100 µg/ml). 
 
LM based vaccine 
The Lm-Mb was developed in an earlier study [11]. This was constructed in the prfA 
negative XFL-7 strain, which lacks the positive regulatory factor A that is a central 
mediator of virulence [27]. The vaccine strain was transformed with LM plasmid pGG-34, 
which encodes prfA and amino acids 311-660 of murine Mage-b fused to a non-cytolytic 
form of Listeriolysin O (LLO) [28]. Complementation of prfA expression by the plasmid 
does not fully restore virulence, but enforces retention of the plasmid during infection 
[27] [28]. 
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Incorporation of !-galactosylceramide into live LM-Mb  
The !GC used in this study was [(2S, 3S, 4R)-1-O-(!-D-galactopyranosyl)-N-
hexacosanoyl-2-amino-1,3,4-octadecanetriol], also known in previous studies as 
KRN7000 or !GalCer-C26:0.  This was synthesized as previously described [29], and 
was stored as solvent-free aliquots in glass vials at -20°C.  The glycolipid was 
reconstituted either in 100% DMSO at 100!M for in vitro studies, or in aqueous vehicle 
consisting of PBS with 0.05% Tween 20 and 0.1% DMSO at 500 !M for in vivo studies.  
The incorporation of !GC into live LM was done using a method similar to that described 
previously for Mycobacterium bovis BCG [25]. Briefly, !GC was solubilized at a 
concentration of 2.3 µM in glass vials by addition of warm (37°C) BHI medium containing 
5% tyloxapol, followed by sonication for 5 min, heating at 80°C for 2 min, and vortexing 
for 1 min.  450 µl of the 2.3 µM solubilized glycolipid was immediately diluted into 50 ml 
of warm BHI to give the required final concentrations of 20 nM glycolipid and 0.05% 
tyloxapol. 500 µl of a LM-Mb mid-log phase culture (OD600 0.5– 0.8) was inoculated into 
this, and grown to mid-log phase (OD600 0.5–1.0), which generally required 4–6 hours. 
The bacterial culture was aliquoted in 1 ml vials and frozen at -80°C.  For subsequent 
use, the bacteria were thawed, harvested by centrifugation, washed three times with 
saline and resuspended in saline for injection. In order to determine the incorporation of 
!GC into LM, we determined the activation of iNKT cell hybridomas by LM or !GC-
incorporated LM infected BMDCs in vitro as described below. As shown in Figure S1, 
BMDCs infected with !GC-incorporated LM elicit a strong iNKT cell response, confirming 
the efficiency of the !GC incorporation. 
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Immunization and tumor challenge 
Mice were challenged with 4T1 tumor cells as described previously [11], and then 
treated using therapeutic vaccination regimens to compare the effects of combined LM-
Mb and !GC treatment either as separate agents or as glycolipid-modified bacteria. 
Briefly, two different immunization protocols were tested. The first immunization protocol 
consisted of three therapeutic immunizations with LM-Mb and !GC.  Mice received 1 x 
104 4T1 tumor cells in the mammary fat pad on day 0, 1 x 104 CFU of LM-Mb or LM or 
saline i.p. on days 3, 6, and 9, and !GC i.p. at the indicated dosage on days 14,15 and 
16.  The second immunization protocol consisted of five therapeutic immunizations with 
LM-Mb modified by direct incorporation of !GC (I-!GC-LM-Mb).  Mice received 1 x 104 
4T1 tumor cells in the mammary fat pad on day 0, and, five therapeutic immunizations 
with 1 x 104 CFU I-!GC-LM-Mb injected i.p. on days 3, 6, 9, 12 and 15.  In studies 
carried out for analysis of the extent of metastatic disease, all mice were euthanized on 
day 18, which was prior to death in saline treated animals, and analyzed for metastases 
and tumor growth. Primary tumors extended to the chest cavity lining, and predominantly 
metastasized to the mesenteric lymph nodes (MLN) (81%), and less frequently to the 
diaphragm (7%) and portal liver (4%), as well as to the surface of spleen (4%) and 
kidneys (4%). Metastases were visible to the naked eye as nodules. The total number of 
metastases per mouse (MLN, diaphragm, liver, kidney and spleen) was determined as 
previously described [11].  For studies carried out to determine effects on survival, mice 
were maintained until they succumbed spontaneously, or were terminated upon 
appearance of severe pre-morbid symptoms requiring euthanasia as specified by our 
approved animal use protocol.  
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Activation of iNKT cells in vivo 
BALB/c mice were immunized i.p with the inert vehicle (PBS plus 0.05% tyloxapol), 1 x 
104 CFU LM, 1 x 104 CFU I-!GC-LM, or 4 nmoles of free !GC (dissolved in PBS plus 
0.01% Tween 20 plus 0.1% DMSO). Sera were assayed at the indicated times for IL-4, 
IL-12p70, and IFN-" by capture ELISA as previously described [30]. Alternatively, 
BALB/c mice receiving 4T1 tumor cells and therapeutic immunizations with LM-Mb or I-
!GC-LM-Mb (see above), were immunized i.p with 4 nmoles of free !GC 15 days after 
the injection of tumor cells. After the indicated times, splenocyte single cell suspensions 
were obtained and stained with anti mouse TCR-FITC (clone H57-597, BD Biosciences) 
and !GC-loaded mouse CD1d tetramers-APC, prepared as previously described[30] 
Samples were acquired using a LSR II Flow Cytometer (BD Biosciences) and analyzed 
using FlowJo software.   
 
Flow cytometry analyses 
Cells were isolated from spleen and blood as described previously[31] [32]. Briefly, red 
blood cells were lysed according standard protocols, and the remaining leukocyte 
population was used for analysis. Cells were first incubated with an Fc blocker (anti-
CD16), and subsequently with specific fluorochrome-conjugated antibodies for the 
identification of different cell types. Anti-CD49b-PerCP5.5 and anti-CD8-PE antibodies 
were used to identify NK cells and CD8 T cells, respectively, and anti-Gr1-PerCP5.5, 
CD11b-Alexa 488 antibodies were used to identify MDSC. Anti-CD45-APC antibody was 
used to identify the leucocyte population in tumor cell suspensions. To detect the 
production of intracellular cytokines, the cytofix/cytoperm kit from Pharmingen was used 
according to the manufacturer’s instructions, and antibodies to IL-12p70 and IFN", were 
used. Appropriate isotype controls were used for each sample. Depending on the 
sample size, data from between 1 x 104 and 2 x 105 cells were acquired using a FACS 
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Calibur flow cytometer (BD Biosciences), and analyzed using Flowjo software as 
described previously [32]. Cell debris and dead cells were excluded from the analyses 
based on forward and side scatter signals and use of Fixable Blue or Green Live/Dead 
Cell Stain Kit (Invitrogen). All antibodies were purchase from BD Biosciences. 
 
ELISPOT 
Spleen cells were isolated from vaccinated and control mice with 4T1 tumors and 
analyzed for T cell responses by ELISPOT as described previously [11]. To detect LM-
induced immune responses, 2 x 105 spleen cells were infected with 2 x 105 CFU of LM 
for 1 hour, and subsequently treated with gentamicin (50 µg/ml) until the end of re-
stimulation (72 hrs). To detect TAA-specific immune responses, 4 x 105 spleen cells of 
vaccinated or control mice were transfected with pcDNA3.1-Mage-b and pCMV-GM-CSF 
using Lipofectamine 2000, as described previously [11]. 72 hrs later, the frequency of 
IFN"-producing cells was determined by ELISPOT according to standard protocols (BD 
Biosciences, San Diego, CA), using an ELISPOT reader (CTL Immunospot S4 analyzer, 
Cellular Technology Ltd, Cleveland, OH). To determine the CD8+ T cell component of 
the responses, spleen cells were depleted of CD8+ T cells using magnetic bead 
depletion techniques according to the manufacturer’s instructions (Miltenyi).  
 
Assessment of toxicity 
Several parameters were used to analyze the toxicity of therapy. Survival was followed 
for up to 18 days, and survival curves plotted for the various treatment groups.  Liver 
toxicity was assessed by visual inspection following sacrifice, and a numerical grade was 
assigned corresponding to the size and number of visible necrotic plaques. The toxicity 
was graded as follows: 0 = no lesions (normal appearance), 1 = uniform light 
discoloration and firmness, 2 = white plaques visible covering ~5% of the liver surface, 3 
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= white plaques covering ~10% of liver surface, 4 = white plaques covering ~20% of liver 
surface, 5 = white plaques covering ~30% of liver surface.  Hematoxylin and Eosin 
(H&E) staining of thin sections of livers was also done to confirm the presence and 
extent of hepatic inflammation and necrosis.  Briefly, liver tissues were fixed in 10% 
formaldehyde for 48 hrs, and then kept in 70% ethanol until use.  Sections of 1 mm thick 
were stained with H&E, and analyzed for pathological damage by light microscopy.  All 
pathological analyses were performed by a trained veterinary pathologist in the Histology 
and Comparative Pathology Core Facility, Albert Einstein College of Medicine.  
 
Statistical analysis 
To statistically analyze the effects of Listeriaat and !GC on the growth of metastases and 
tumors and immune responses in the 4T1 model, the Mann-Whitney test and for the 
survival studies the Mantel-Cox test were used. Values p<0.05 were considered 
statistically significant. *p<0.05, **<0.01, ***<0.001, ****<0.0001 is significant. 
 
 
Results  
Efficacy of combination therapy with LM-Mb and !GC in metastatic breast cancer 
The therapeutic effect of combining the Lm-Mb vaccine with #GC treatment on 
metastatic breast cancer was assessed in the 4T1 transplantable mouse tumor model. 
This combination was tested with !GC administered as a free glycolipid, and also using 
a protocol to physically incorporate the glycolipid into the live bacterial vaccine.  This 
latter approach has been shown by us in previous work on the mycobacterial vaccine 
strain BCG, in which !GC incorporation was successfully achieved, to elicit more robust 
CD8+ T cell responses [25]. Mice treated with unmodified LM-Mb showed marked 
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reduction in metastases when sacrificed at day 18 after initial tumor implantation (Figure 
1A), consistent with previous studies showing that this treatment induces a variety of 
tumoricidal mechanisms.  An improved anti-metastatic effect was observed with LM-Mb 
compared to LM, suggesting an effect of Mage-b specific immunity, and also with !GC 
administered as a single agent.  Strikingly, the combination of !GC with LM-Mb, either 
as a separately administered agent (LM-Mb + !GC) or by direct incorporation of the 
glycolipid into the live bacteria (I-!GC-LM-Mb), gave a significantly better anti-metastatic 
effect compared to LM-Mb alone or !GC alone.  Both of the regimens using combined 
LM-Mb and !GC treatment reduced the number of macroscopically visible metastases 
nearly to zero, with only a rare nodule being detected in these mice. Significant 
reductions in the weights of primary tumors were also observed in all treatment groups, 
although combination treatment did not show significant improvement over single agent 
treatment in this parameter (Figure 1B). 
 
Direct incorporation of !GC into LM-Mb avoids severe toxicity 
Although !GC appeared to be equally efficacious when administered as a free glycolipid 
following LM-Mb treatment or simultaneously using the direct incorporation approach, 
analysis of survival of treated mice revealed a striking difference between these two 
approaches.  Whereas all untreated 4T1 bearing mice (i.e., saline injections only) 
survived at least 18 days from the time of tumor initiation, we observed a significant 
fatality rate starting around day 11 in animals treated with the sequential administration 
of LM-Mb and !GC as separate agents.  In contrast, no deaths were observed over this 
time period in any of the other treatment groups, including those which received LM-Mb 
directly incorporated with !GC (I-!GC-LM-Mb) (Figure 2A).  Visual inspection revealed 
obvious white plaques on the surface of the livers only in animals receiving the 
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separately injected LM-Mb and !GC, suggesting focal areas of hepatic necrosis.  This 
was verified by histologic studies of thin sections of the liver, which revealed foci of 
necrosis in mice that received the two agents as separate series of injections (Figure 
2B).  Such foci were also observed with lower frequency and smaller size in mice that 
received !GC alone, but not at all in animals that were treated with I-!GC-LM-Mb or LM-
Mb alone (Figure 2C).  We then carried out a more extended survival study to compare 
time to death in 4T1 tumor bearing mice receiving therapeutic vaccination with I-!GC-
LM-Mb versus mice receiving only saline injections. As shown in Figure 2D, while mice 
that received only sham immunizations with saline all succumbed by day 20, mice that 
received I-!GC-LM-Mb all survived past day 20 and showed a significant extension 
(30%) of overall survival.  This extension of survival was consistent with the marked anti-
metastatic effect and low toxicity of the I-!GC-LM-Mb treatment.  
 
Activation of NKT cells in spleens of 4T1 tumor-bearing mice that received I-!GC-
LM-Mb 
To determine whether Listeriaat bacteria modified by direct incorporation of !GC could 
activate NKT cells in vivo, we assessed the rapid production of IFN" and IL-4, two 
cytokines that are charactistically produced by NKT cells. For this purpose we injected 
naïve mice once with LM, !GC or I-!GC-LM and obtained serum samples at various 
time points after injection to determine cytokine levels. Previous studies have shown that 
!GC administered as a free glycolipid induces the production of IFN" and IL-4 which 
peak in the serum at approximately 12 hours and 2 hours, respectively [25].  Infection 
with LM also induces the production of IFN" by NKT cells and macrophages [33]. We 
found that I-!GC-LM stimulated a serum IFN" response that was apparent at 12 hours, 
and peaked at 24 hours.  In contrast, LM infection generated a large transient serum 
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IFN" response which was first detected at 24 hours (Figure 3A).  The accelerated IFN" 
production seen with I-!GC-LM was consistent with direct NKT cell activation by the 
!GC incorporated into the bacteria.  Also supporting the conclusion that NKT cells were 
directly activated, we observed a significant IL-4 response at 2 hours after injection of I-
!GC-LM, whereas LM alone did not stimulate detectable IL-4 (Figure 3B).   To confirm 
that NKT cells were rapidly activated by treatment with I-!GC-LM-Mb in tumor-bearing 
mice in vivo, we analyzed the percentages of NKT cells in the spleens of 4T1 tumor-
bearing mice that were therapeutically immunized with I-!GC-LM-Mb using CD1d 
tetramers loaded with !GC.  The percentage of NKT cells stained with the tetramer 
reagent detected in the spleens of tumor-bearing mice that had received 5 therapeutic 
treatments with I-!GC-LM-Mb was either unchanged or slightly increased compared to 
saline or LM treated controls (Figure 4AB).  This indicated that administering !GC in 
this form did not cause systemic depletion of NKT cells, which is a potential problem that 
has been associated with treatments using systemic repeated administrations of !GC as 
a free glycolipid. Furthermore, when similarly treated mice were injected with free !GC, 
their tetramer binding NKT cells showed a transient decrease in the spleen at 12 hours, 
followed by a rebound to greater than baseline levels at 72 hours (Figure 4AB).  This 
pattern was consistent with the normal activation pattern observed for intact NKT cell 
populations in healthy naïve mice, which is characterized by TCR down modulation 
leading to loss of tetramer staining at earlier time points followed by TCR re-expression 
and expansion of the tetramer staining population due to proliferation by 72 hours. In 
fact, both LM-Mb and I-!GC-LM-Mb showed significant increases in the expansion of 
NKT cells at 72 hours, with I-!GC-LM-Mb showing the greater effect (Figure 4AB).  
  In summary, these results indicated that NKT cell activation by repeated I-
!GC-LM-Mb treatments did not lead to either depletion or anergy of NKT cells in vivo, 
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and may actually have primed NKT cells to respond more vigorously to subsequent 
stimulation. 
 
The effect of I-!GC-LM-Mb treatment on circulating MDSC 
In mice, MDSC express both the myeloid lineage differentiation antigen Gr1 (Ly6C and 
Ly6G) and the !M integrin CD11b. Two major groups of MDSC have been described: 
CD11b+Gr1high (CD11b+Ly6G+Ly6Clow) with a granulocytic phenotype (gMDSC), and 
CD11b+Gr1low (CD11b+Ly6G-Ly6Chigh) with a monocytic phenotype (mMDSC) [34, 35]. 
MDSCs are present in large numbers in blood of mice and humans with cancer [36, 37]. 
We found that the percentage of MDSC was extremely high in blood of the 4T1 model 
(#80%), while in non-tumor-bearing mice MDSC hardly detectable (#3%)(Figure S2AB).  
Since LM has been shown to infect MDSC[38], we analyzed the effect of I-#GC-
LM-Mb on the levels of these circulating MDSC.  Although our regimen of five therapeutic 
injections with #GC alone reduced the percentage of total and gMDSC in the blood of 
tumor-bearing mice by 39% compared to the saline group, all other treatment groups 
including I-#GC-LM-Mb had little effect on the levels of these cells (Figure 5A). 
MDSC strongly suppress T cell and NK cell responses in the TME [39],[40].  
Moreover, they are associated with the production of immunosuppressive cytokines such 
as IL-10 [41] and suppression of pro-inflammatory IL-12p70, [17],[42]. Therefore, we 
analyzed the production of IL-12p70 by gMSDC and mMDSC populations in the blood of 
4T1 tumor bearing mice treated with our various regimens.  All treatments showed a 
trend toward increased IL-12p70 production by both circulating myeloid cell subsets, but 
this rose to a statistically significant level only in mice treated with I-!GC-LM-Mb, and 
only in mMDSC  (Figure 5B). We also assessed IL-12p70 production by MDSC isolated 
from primary tumors of these mice, but significant levels of IL-12 were not observed (data 
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not shown). Overall, these results indicated a significant effect of I-!GC-LM-Mb treatment 
on mMDSC, and a shift to more pro-inflammatory and less suppressive function was 
observed in MDSC outside of the TME. 
 
Improved T cell and NK cell responses in mice vaccinated with I-!GC-LM-Mb 
The activation of NKT cells has been frequently shown to lead secondarily to increased 
CD8+ T cell cross-priming and to NK cell activation, and both of these processes are 
assisted by IL-12p70 [17].  Given that NKT cell activation and IL-12p70 production by 
mMDSC were both augmented by treatment of tumor bearing mice with I-!GC-LM-Mb, 
we analyzed whether this treatment could also enhance CD8+ T cell and NK cell 
responses using the production of IFN" as an activation marker. First, we analyzed CD8+ 
T cell responses to Mage-b in the spleens of I-!GC-LM-Mb treated and control mice 
upon re-stimulation with Mage-b in vitro by measuring extracellular IFN" using ELISPOT.  
This showed a significantly higher number of Mage-b-specific CD8+ T cells producing 
IFN" in the spleens of mice treated with I-!GC-LM-Mb than in mice treated with either 
LM-Mb or !GC alone (Figure 6A). Similarly, by enumerating CD8 T cells producing 
intracellular IFN" (as a results of the in vivo treatments) in peripheral blood samples by 
flow cytometry (without in vitro re-stimulation), a higher response was evident in mice 
treated with I-!GC-LM-Mb compared to mice treated with Lm-Mb or !GC alone (Figure 
6B).  These results indicated a superior effect of I-!GC-LM-Mb on stimulating the cross-
priming of CD8+ T cells specific for tumor associated antigens. 
 We also analyzed NK cell responses by measuring extracellular IFN" using 
ELISPOT in I-!GC-LM-Mb treated and control mice following in vitro infection of 
splenocytes with LM.  This showed significant increase in the number of IFN"-producing 
NK cells in I-!GC-LM-Mb treated mice compared to mice treated with saline, or with LM-
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Mb or !GC alone (Figure 6C).  In addition, analysis of the intracellular IFN" production 
by NK cells in blood (as a result of in vivo treatments) by flow cytometry (without any re-
stimulation in vitro), showed that the percentage of activated circulating NK cells was 
significantly higher in mice that received I-!GC-LM-Mb than LM-Mb or !GC alone, or 
saline (Figure 6D).  
 
 
Discussion 
While treatment with !GC as a free glycolipid injection has shown remarkable anti-tumor 
activity in a variety of mouse models of cancer, phase I clinical trials of this approach in 
human cancer patients have not shown clear evidence of therapeutic benefit[43] 
Improvements in this approach by using immunizations with !GC pulsed autologous 
DCs, or by infusing ex vivo expanded NKT cells, are currently being studied.  While 
these approaches may increase the ability to harness anti-tumor properties of NKT cells 
for cancer immunotherapy, they are complicated and difficult to administer.  In the study 
presented here, we have developed a simple approach for combining !GC with a 
Listeria monocytogenes-based tumor vaccine to achieve strong synergistic effects, 
particularly in the suppression of metastatic disease.  We showed that !GC significantly 
improved therapeutic efficacy of a LM-based vaccine expressing the TAA Mage-b in a 
highly metastatic mouse breast tumor model using the transplantable 4T1 cell line. The 
combination of LM-Mb with !GC, with the glycolipid administered either as a separate 
series of injections or directly incorporated into the LM-Mb bacteria, was highly effective 
at reducing the number of metastases, and almost completely eliminated grossly visible 
metastatic nodules.  Most significantly, while the administration of LM-Mb and !GC as 
separate injections in sequential fashion was associated with marked toxicity due to 
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hepatic necrosis, we found that the direct incorporation of the glycolipid into LM-Mb 
completely eliminated the toxicity while still preserving the marked clinical benefit. 
  The potential for !GC to induce foci of necrosis in the liver of mice is well 
documented, and is believed to be related to the very high frequency of NKT cells that 
are resident in the liver in this species [44].  Humans have a much lower frequency of 
NKT cells in liver tissue [45, 46], and hepatic toxicity following administration for !GC to 
humans has not been observed [47, 48].  Nevertheless, the combination of LM-Mb and 
!GC has never been tested in humans, and the possibility that infection with LM could 
prime the liver to become sensitive to toxic effects of !GC is an important consideration. 
Therefore, our alternative method using live LM-Mb with !GC directly incorporated into 
the bacteria (I-!GC-LM-Mb) represents an extremely practical and potentially safer 
approach to administering this combination immunotherapy.  To produce I-!GC-LM-Mb, 
we used an approach that was similar to that used previously to successfully incorporate 
!GC into live M. bovis BCG organisms [25].  This method involves simply growing the 
bacteria in suitable protein-free medium in the presence of low concentrations of a 
detergent (tyloxapol) and the synthetic glycolipid.  In studies with BCG, we found that 
approximately 25-35% of the glycolipid became stably associated with the bacteria, most 
likely through direct intercalation into the bacterial cell wall and membrane.  Although the 
extent and mechanism of association of !GC with LM bacteria modified in this way have 
not been studied, the glycolipid incorporation resisted extensive washing of the modified 
bacteria suggesting possible intercalation into the bacterial membrane.  The LM 
organisms modified in this way maintained full viability, and acquired the ability to rapidly 
activate NKT cells in culture (data not shown) and in vivo (Figure 3). 
 Although the incorporation of !GC into LM-Mb was similar to the M. bovis BCG, 
their mechanisms in activating T cells may be different. Since LM infects CD8!+DC [49], 
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we expect that I-!GC-LM-Mb also infects and matures these DC. Moreover, it is likely 
that the high efficiency of infection of CD8!+DC with LM, resulted in a much higher 
intracellular concentration of !GC compared to the uptake of free !GC. In addition to 
monocytes, macrophages and CD8!+ DC, LM also infects MDSC [38], which is 
particularly important in cancer because they are present in large numbers in blood of 
tumor bearing humans and mice [36], including the 4T1 model as we have shown in this 
study.  These cells are known for their strong suppression of T cells and NK cells in the 
TME through the production of cytokines such IL-6, IL-10, and TGF$, or factors such as 
arginase and iNOS [39], [12].  Our analyses of circulating MDSC populations in mice 
immunized with I-!GC-LM-Mb suggested a conversion of mMDSC, and less pronounced 
of gMDSC, to an immune-stimulating phenotype producing IL-12p70. This correlated 
with improved CD8+ T cell responses to Mage-b and increased NK cell activation in vitro 
and in vivo. Others have shown that !GC or LM increases the production of IL-12p70 in 
naïve mice, resulting in improved T cell responses [42]. Our results suggest that the IL-
12p70 induced by I-!GC-LM-Mb in the 4T1 model may have improved the T cell 
responses to Mage-b and NK cell responses to LM. The metastases and primary tumor 
highly express Mage-b and are therefore a target for Mage-b-specific CD8 T cells. In a 
previous study we have shown that LM also infects tumor cells and activates CD8 T cells 
and NK cells[14]. Therefore, LM-infected tumor cells are a sensitive target for LM-
activated T cells [14], which may also have contributed to tumor cell destruction in vivo. 
 While I-!GC-LM-Mb was extremely effective against the metastases, it was less 
effective against the primary tumors.  In humans and mice the number of MDSC in the 
blood is much higher than in the primary tumor [36]. We observed increased levels of IL-
12p70 in mMDSC by I-!GC-LM-Mb in the blood, but not in the primary tumors. Similarly, 
improved T cell activation by I-!GC-LM-Mb was detected in the blood but not in the 
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primary tumors.  These may be the reasons why our I-!GC-LM-Mb treatment were more 
effective against the metastases, that usually spreads via the blood stream, than against 
the primary tumors. 
 
Conclusions 
 In summary, we demonstrated that a novel combination of a recombinant LM 
expressing Mage-b and directly incorporated with !GC almost completely eliminated 
metastases in the 4T1 model without toxicity. Our results suggest that activation of NKT 
cells, NK cells and CD8 T cells, as well as the interaction between I-!GC-LM-Mb and 
mMDSC have contributed to this success. The almost complete elimination of the 
metastases is of crucial importance because patients usually die of metastases and not 
of their primary tumor.  Moreover, standard therapies such as surgery, chemotherapy 
and radiotherapy are quite successful against primary tumors, but not against 
metastases.  Therefore, standard therapy to eliminate the primary tumor combined with 
a treatment of I-!GC-LM expressing and appropriate TAA to eliminate metastases could 
be a promising new approach to treat metastatic breast and perhaps other metastatic 
cancers.  
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Figure Legends 
Fig 1: Therapeutic immunizations with Lm-Mb+!GC or I-!GC-LM-Mb are equally 
effective against metastatic breast cancer (4T1 model). BALB/c mice were 
challenged with 4T1 tumor cells in the mammary fat pad and immunized therapeutically 
(ip) three times with Listeriaat-Mage-b (LM-Mb) and #-galactosylceramide (#GC) as 
combination (LM-Mb+#GC) or five times with LM-Mb incorporated with #GC (I-#GC-LM-
Mb).  Mice were euthanized one day after the last immunization and analyzed for the 
frequency of metastases (A) and tumor weight (B). This experiment was performed 
three times with 5 mice per group, and the results were averaged. Mann-Whitney p<0.05 
is significant. *<0.05, **<0.01, ***<0.001, ****<0.0001. The combination of LM-Mb+#GC 
or I-#GC-LM-Mb was compared to the LM-Mb or #GC alone, and I-#GC-LM-Mb was 
compared to LM-Mb+#GC. All groups were significantly different from the saline group. 
The error bars represent the standard error of the mean (SEM).  
 
Fig 2: !GC is toxic in combination with LM-Mb but not when incorporated into LM-
Mb in 4T1 tumor bearing mice. 
BALB/c mice were challenged with 4T1 tumor cells and immunized with LM-Mb+#GC or 
I-#GC-LM-Mb and controls as described in Fig. 1. The percentage of live animals was 
determined in all groups 18 days after tumor cell injection. Mice treated with LM-
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Mb+#GC only died between 12 and 18 days (A). This experiment was repeated three 
times with 5 mice per group and the results were averaged. Mantel-Cox p<0.05 is 
significant. Sections of the liver of mice that received LM-Mb+#GC or I-#GC-LM-Mb 
were stained with H&E and analyzed by light microscopy. Foci of necrosis were found in 
mice immunized with LM-Mb+#GC (see black arrow) but not in mice that received with I-
#GC-LM-Mb (B). The boxed areas on the left side of the figure are shown in larger 
magnification on the right side. Graph is a representative of 2 experiments. The toxicity 
grade in the liver was determined by the naked eye (C). The toxicity graded was 
quantified as follow: 0=no toxicity, 1=uniformly light tanned and firm, 2=5% of the liver is 
covered by white plaques, 3=10% of the liver is covered by white plaques, 4=20% of the 
liver is covered by white plaques, 5=30% of the liver is covered by white plaques. This 
experiment was repeated three times with 5 mice per group and the results were 
averaged. In addition, the survival time of mice that received I-#GC-LM-Mb or saline 
were compared. For this purpose, BALB/c mice were challenged with 4T1 tumor cells 
and immunized with I-#GC-LM-Mb and saline as described in Fig. 1, but in this 
experiment mice received 7 instead of 5 immunizations. I-#GC-LM-Mb-treated 4T1 
tumor-bearing mice lived significantly longer than the saline control group (D). This 
experiment was performed once with 8 mice per group. Mantel-Cox p<0.05 is significant.  
 
Fig. 3: Immunizations with I-!GC-LM in naïve mice induce a rapid production of 
IFN"  and IL-4. Naïve BALB/c mice were injected once with LM, !GC or I-!GC-LM and 
serum samples were obtained at various time points after injection to determine the IFN" 
levels (A) or at 2 hours after injection to determine the IL-4 levels (B) by ELISA. Graphs 
is representative of three experiments.  
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Fig. 4: Repeated therapeutic immunizations with I-!GC-LM do not anergize NKT 
responses in the spleen of 4T1-tumor-bearing mice. BALB/c mice were challenged 
with 4T1 tumor cells and immunized with I-#GC-LM-Mb as described for Fig. 1. After 15 
days of the first immunization, splenocytes were obtained and stained for iNKT cells 
using !GC-loaded CD1d tetramers (0 hrs time point). In parallel, a group of mice 
receiving the same treatment was injected i.p. with free !GC and splenocytes were 
stained for iNKT cells after 12 and 72 hours. Representative dot plots showing TCR and 
!GC-loaded CD1d tetramers staining are shown in (A), and the summarized data with 
three mice per group is shown in (B). Mann-Whitney * and ** represent p<0.05 and p 
0.01, respectively. 
 
Fig 5: Therapeutic immunizations with I-!GC-LM-Mb reduce the percentage of 
MDSC and improve IL-12 production by MDSC in blood of 4T1 tumor-bearing mice. 
BALB/c mice were challenged with 4T1 tumor cells and immunized with I-#GC-LM-Mb 
as described in Fig. 1. The total MDSC population (CD11b+Gr1+), the gMDSC population 
(CD11b+Gr1high) and mMDSC population (CD11b+Gr1low) were gated within total live 
leukocyte population in blood and analyzed by flow cytometry. This experiment was 
repeated 3 times with n=3-5 mice per group and the results were averaged (A). Mann-
Whitney p<0.05 is significant. *<0.05, **<0.01, ***<0.001, ****<0.0001. The production of 
IL-12 by mMDSC and gMDSC was analyzed in blood by flow cytometry. A 
representative example of gating MDSC populations by flow cytometry is provided in the 
Supplementary Information (Figure S3A). The mMDSC and gMDSC producing IL-12 
were gated in the live MDSC population. This experiment was repeated 3 times with 
n=3-5 mice per group and the results were averaged (B). Mann-Whitney p<0.05 is 
significant. *<0.05, **<0.01, ***<0.001, ****<0.0001. In both figures I-#GC-LM-Mb was 
compared to LM-Mb or #GC alone. The error bars represent the SEM. A representative 
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flow cytometry profile of MDSC producing IL-12 is provided in the Supplementary 
Information (Figure S3B). 
 
Fig 6: Therapeutic immunizations with I-!GC-LM-Mb improve CD8 T cells and NK 
cells responses in blood and spleen of 4T1 tumor-bearing mice. BALB/c mice were 
challenged with 4T1 tumor cells and immunized with I-#GC-LM-Mb as described in Fig. 
1, and analyzed for Mage-b-specific T cell responses and NK cell responses to LM in 
vitro and in vivo. For Mage-b-specific CD8 T cell responses in vitro, the number of CD8 
T cells producing extracellular IFN" per 400,000 spleen cells of I-#GC-LM-Mb and 
control mice was determined by ELISPOT after re-stimulation with Mage-b (A). CD8 T 
cells were depleted by magnetic beads technique. Spleens of 5 mice per group were 
pooled. This experiment was repeated 2-3 times and the results were averaged. I-#GC-
LM-Mb was compared to LM-Mb or #GC alone. Mann-Whitney p<0.05 is significant. 
*<0.05, **<0.01, ***<0.001, ****<0.0001. The error bars represent the SEM. For in CD8 T 
cell responses in vivo, the percentage of CD8 T cells producing intracellular IFN" was 
determined by flow cytometry in blood of I-#GC-LM-Mb and control mice without any re-
stimulation (B). The CD8 T cells were gated within total live lymphocyte population in 
blood. Mice were analyzed individually. n=5 mice per group. This experiment was 
repeated 3 times and the results were averaged. I-#GC-LM-Mb was compared to LM-Mb 
or #GC alone. Mann-Whitney p<0.05 is significant. *<0.05, **<0.01, ***<0.001, 
****<0.0001. The error bars represent the SEM. For NK cell responses to LM in vitro, the 
number of NK cells producing extracellular IFN" per 200,000 spleen cells of I-#GC-LM-
Mb and control mice was determined by ELISPOT after infection with LM (C). NK cells 
were depleted by magnetic beads technique. Spleens of 5 mice per group were pooled. 
This experiment was repeated 2-3 times and the results were averaged. I-#GC-LM-Mb 
was compared to LM-Mb or #GC alone. Mann-Whitney p<0.05 is significant. *<0.05, 
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**<0.01, ***<0.001, ****<0.0001. The error bars represent the SEM. For NK cell 
responses in vivo, the percentage of NK cells producing intracellular IFN" was 
determined by flow cytometry in blood of I-#GC-LM-Mb and control mice without any re-
stimulation (D). The NK cells were gated in the total live lymphocyte population. I-#GC-
LM-Mb was compared to LM-Mb or #GC alone. This experiment was performed 3 times 
n=3-5 mice per group and the results were averaged. Mann-Whitney p<0.05 is 
significant. *<0.05, **<0.01, ***<0.001, ****<0.0001. The error bars represent the SEM.  
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Figure S1: Bone marrow dendritic cells infected with I-!GC-LM induced efficient 
iNKT cell activation in vitro. BALB/c derived BMDCs were infected with LM or I-!GC-
LM at different multiplicity of infection, for 3 hours and then co-cultured with an iNKT cell 
hybridoma for 24 hours. As a control, BMDCs were pulsed with 100 nM of free !GC and 
then co-cultured with the iNKT cell hybridoma for 24 hours. After the co-culture, IL-2 
levels were determined in the supernatants by ELISA. For more detailed information see 
M and M below. 
 
Figure S2: MDSC were present in large numbers in tumor-bearing mice but not in 
naïve mice. MDSC populations were analyzed in blood of tumor-bearing and naive 
BALB/c mice. MDSC (CD11b+Gr1+)(top and bottom box), gMDSC (CD11b+Gr1high)(top 
box) and mMDSC (CD11b+Gr1low)(bottom box) were gated within total live leukocyte 
population in blood and analyzed by flow cytometry (A). n=3 mice per group. This 
experiment was performed 2-3 times, and the results were averaged and summarized 
(B). 
 
Figure S3: A representative flow cytometry profile of MDSC populations and 
MDSC producing IL-12. BALB/c mice were challenged with 4T1 tumor cells and 
immunized with I-!GC-LM-Mb as described in Fig. 1 of the manuscript. MDSC 
(CD11b+Gr1+)(top and bottom box), gMDSC (CD11b+Gr1high)(top box) and mMDSC 
(CD11b+Gr1low)(bottom box) were gated within total live leukocyte population in blood 
and analyzed by flow cytometry (A). The mMDSC and gMDSC producing IL-12 were 
gated in the live MDSC population (B). This experiment was repeated 3 times with n=3-5 
mice per group.  
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Materials and Methods 
 
Activation of iNKT cell hybridoma in vitro 
Day 9 BMDCs were infected with different MOIs (0.1, 0.5 and 1) of LM or I-!GC-LM 
during 3 hours at 37°C, treated with gentamicin (100 ug/ml) for 1 hour to remove 
extracellular bacteria and cultured overnight. Then, BMDCs were co-cultured with 
DN3A4-1.2 mouse iNKT cell hybridomas (5 x 104 BMDCs and 5 x 104 iNKTs/well in 96 
well plates). BMDCs treated with 100 ng/ml of !GC were included as positive control. 
After 24 hours of co-culture, IL-2 secretion in the supernatants was determined by 
capture ELISA as described previously1 
 
 
1 Castro, F. et al. Vaccination with Mage-b DNA induces CD8 T-cell responses at 
young but not old age in mice with metastatic breast cancer. Br J Cancer 101, 
1329-1337, doi:10.1038/sj.bjc.6605329 (2009). 
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CHAPTER 4 
 
GENERAL DISCUSSION 
 
Problems and promises of cancer vaccination 
Immune suppression is a major problem in cancer vaccination or cancer 
immunotherapy. Various approaches have been used in mice and humans to reduce 
immune suppression in cancer. This includes elimination of immune cells that induce 
immune suppression such as Treg (using anti-CD25 antibodies) and MDSC (using anti-
Gr1 antibodies), or by agents such fish oil and selenium (eliminates Tregs and MDSC), or 
a streptococcal extract OK432 (eliminates Tregs), a glycan-binding protein Galectin-1 
(eliminates Tregs), or antibodies that can block co-inhibitory molecules such anti-CTLA-4 
or anti-PD-1138-143. Since immune suppression involves a combination of inhibitory 
cytokines, factors, receptor-ligand interactions, various approaches will be necessary to 
sufficiently reduce the immune suppression until a level that allows T cells to react to the 
tumor cells. Also different tumors may induce different types of immune suppression. 
Therefore, depending on the type of immune suppression a suitable combination therapy 
could be designed to improve cancer vaccination through reduction of immune 
suppression.  
 In the thesis presented here we focused on the immune suppression in metastatic 
breast cancer. The production of IL-6 is one of the main cytokines that play an important 
role in immune suppression in breast cancer, and particularly in TNBC125,144. TNBC are 
enriched for stem-like breast cancer cells (CD44+/CD24-/low), which are typically 
aggressive and highly resistant to current therapies145-147. These stem-like breast cancer 
cells produce high levels of IL-6, and have the capacity to metastasize137. Moreover, IL-6 
is capable of converting dormant breast cancer cells into an actively growing tumor. 
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While most breast cancers in an early stage are curable, TNBC is incurable. It lacks the 
expression of ER, PR, and HER2, which leaves highly toxic therapies as only option, 
and ultimately does not cure the cancer. Therefore, in this thesis project we selected a 
metastatic mouse tumor model 4T1 with TNBC, which is highly aggressive and 
metastatic, and their tumors and metastases produce high levels of IL-6148.  
  
Increasing the success rate of cancer vaccination or immunotherapy by reducing 
IL-6 
As mentioned above, one of the main problems with treatments against TNBC is the 
high toxicity. Therefore, we focused in this thesis on non-toxic vaccine therapies against 
metastatic breast cancer using a TNBC model 4T1. As shown here in this thesis, the 
combination therapy of Listeriaat-Mage-b and curcumin is non-toxic, but induced 
primarily inflammatory responses in the spleen and liver. Curcumin was selected 
because it is known for reducing IL-6, and IL-6 is one of the main contributors to immune 
suppression in the TME, particularly in TBNC. In this thesis (see Chapter 2), we tested 
whether curcumin could improve the efficacy (effect on metastases and tumor) of 
Listeriaat-Mage-b vaccine, through reduction of IL-6, and improved T cell responses to 
Mage-b. Various immunization protocols have been tested. In the first immunization 
protocol with Listeriaat-Mage-b and curcumin both therapeutically administered, we found 
that curcumin significantly improved the efficacy of Listeriaat-Mage-b vaccination 
resulting in a strong reduction in the number of metastases compared to all control 
groups. Also Listeriaat-Mage-b alone reduced the number of metastases and tumor 
growth significantly but less robust than the combination, while curcumin alone did not 
have much effect on the metastases or tumors. Others found an anti-tumor effect of 
curcumin on tumor cells in vitro117-121. However, tumor cells may react differently in vitro 
to curcumin than in vivo because in vitro bioavailability and the immune system does not 
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play a role and higher concentrations can be obtained in vitro compared to the in vivo 
situation. Also, the time point of administering curcumin, the concentration of curcumin, 
and the type of cancer may determine the anti-tumor effect of curcumin. For instance, 
others reported that the time point of administration of curcumin is important149. We 
found that administering curcumin before tumor development was more effective than 
after tumor development. Since curcumin has been consumed in food all over the world 
we tested administration of curcumin before and Listeriaat-Mage-b after tumor 
development. This combination therapy was significantly more effective against the 
metastases compared to the administration of curcumin and Listeriaat-Mage-b after 
tumor development. Moreover, administration of curcumin before tumor development 
was more effective against metastases and tumor weight than curcumin administered 
after tumor development.  
 The almost complete elimination of the metastases and strong reduction in tumor 
weight by curcumin before and Listeriaat-Mage-b after tumor development correlated 
with reduction in IL-6 levels in the primary tumors and in MDSC in blood, and 
significantly improved T cell responses to Mage-b in vivo and in vitro. However, the 
effect on primary tumor was less compared to metastases, in correlation with lower T 
cell responses. Not only curcumin reduced the IL-6 levels in the tumor cell lysates, but 
also Listeriaat-Mage-b, and the strongest reduction was observed with the combination of 
Listeriaat-Mage-b and curcumin. In addition, we found that the combination therapy 
significantly reduced the number of MDSC and converted a remaining sub population of 
MDSC into an immune stimulating phenotype in blood but not in primary tumors, 
producing IL-12. IL-12 is known for activating naïve and mature T cells62,150. The 
combination therapy significantly increased CD8 T cell responses to Mage-b in vitro and 
in vivo. Most interesting was that the combination therapy significantly reduced the 
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percentage of MDSC in blood but not in primary tumors, and may have contributed to 
the more significant effect on metastases than on primary tumors. 
In summary, the results accumulated in this study, i.e. (1) reduction of IL-6 in the 
primary tumor and MDSC, (2) increase in IL-12 production by MSDC, (3) reduction in the 
percentage of MDSC, and (4) improved CD8 T cell responses to Mage-b in vitro and in 
vivo, strongly suggest that our combination therapy of Listeriaat-Mage-b and curcumin 
improved the therapeutic effect of Listeriaat-Mage-b through improvement of T cell 
responses to Mage-b in a TNBC model 4T1. The potential pathways of Listeriaat-Mage-b 
and curcumin involved in anti-tumor responses analyzed in this study are summarized in 
Fig 1. While curcumin alone may have less therapeutic value, as adjuvant with vaccines 
it is a powerful tool to reduce immune suppression in the TME, and show great promise 
for clinical application in other IL-6-producing cancers.  
 
Creating an immune-stimulating environment with !GC to help adaptive and 
innate immune responses against metastatic breast cancer 
One way to improve T cell responses is by reducing immune suppression in the TME. 
Here we used another approach. !GC is a glyclipid that is a strong activator of NKT 
cells, resulting in a cascade of Th1 cytokines such as IFN" and IL-12 among others (IL-
4, IL-13), and basically converts an immune suppressing into an immune-stimulating 
environment. Initially we started testing the combination of free !GC and Listeriaat-Mage-
b in the TNBC model 4T1. While the effect on metastases was very impressive, i.e. we 
observed an almost complete elimination of the metastases, it appeared that the 
combination was highly toxic in the liver. Therefore, we used a novel approach by 
incorporating the !GC into the cell wall of live Listeriaat-Mage-b (I-!GC-LM-Mb). This 
approach was successfully used earlier for Mycobacteria showing improved CD8 T cell 
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stimulation151. While the administration of LM-Mb and !GC as separate injections in 
sequential fashion was associated with marked toxicity due to hepatic necrosis, we 
found that the direct incorporation of the glycolipid into LM-Mb completely eliminated the 
toxicity while still preserving the marked clinical benefit. Repeated immunizations with 
low dose of I-!GC-LM-Mb almost completely eliminated all metastases without any liver 
toxicity. This correlated with the activation of NKT cells, the production of IL-12p70 by 
MDSC, and the subsequent activation of NK cells and Mage-b-specific CD8 T cells in 
blood in vivo. 
Obvious was that the I-!GC-LM-Mb was less effective on CD8 T cells and NK 
cells in the primary tumor. In humans and mice the number of MDSC in the blood is 
much higher than in the primary tumor152. We observed the increased levels of IL-12p70 
in myeloid cells in the blood, but not in the primary tumors. Similarly, improved T cell and 
NK cell activation was detected in the blood but not in the primary tumors. These may be 
the reasons why our I-!GC-LM-Mb treatment were more effective against the 
metastases, that usually spreads via the blood stream, than against the primary tumors. 
 In summary, we demonstrated that a novel combination of a recombinant LM 
expressing Mage-b and directly incorporated !GC almost completely eliminated 
metastases in the 4T1 model without toxicity. This is of crucial importance because 
patients usually die of metastases and not of their primary tumor.  Moreover, standard 
therapies such as surgery, chemotherapy and radiotherapy are quite successful against 
primary tumors, but not metastases.  Therefore, standard therapy to eliminate the 
primary tumor combined with a treatment of I-!GC-LM-Mb expressing and appropriate 
TAA to eliminate metastases, could be a promising new approach to treat metastatic 
breast and perhaps other metastatic cancers. The potential pathways of I-!GC-LM-Mb 
involved in anti-tumor responses, analyzed in this study are summarized in Fig 2. 
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Our previous and current results strongly suggest that not only Mage-b-specific T 
cells cause tumor cell destruction. We have shown that Listeriaat infected tumor cells and 
killed tumor cells through high levels of ROS, and that infected tumor cells were 
sensitive targets for LM-activated T cells114. The multiple pathways of Listeriaat, i.e. 
delivering TAA and !GC with extreme high efficiency into APC, infecting and converting 
MDSC when combined with curcumin or incorporated with !GC into an immune-
stimulating phenotype producing IL-12, and infecting and killing tumor cells through 
ROS, with practically no side effects, makes Listeriaat highly attractive for cancer 
immunotherapy.  
  
Future prospects of cancer vaccination 
As we have shown here in mice with metastatic breast cancer (4T1 model), vaccines 
can be effective against metastases, but only if the immune suppression is reduced or 
converted into immune stimulation. Also important is that both combination therapies are 
non-pathogenic and non-toxic. This opens up the possibility to use these combination 
therapies as second line therapy after removal of the primary tumor by surgery, 
chemotherapy or radiation. Often, the second line therapy is administered after 
metastases have been detected, because of its high toxicity. Our non-toxic combination 
therapies could be administered in an early phase after first line therapy (without 
knowing if metastases will develop), to prevent recurrence or the development of 
metastases.  
One question that arose in both studies, i.e. with Listeriaat-Mage-b and curcumin 
or with I-!GC-LM-Mb, what the value was of the in vitro re-stimulation assays with 
Mage-b versus the in vivo analysis of CD8 T cells by flow cytometry without any re-
stimulation. As described above, it was obvious that in both studies the in vivo analysis 
by flow cytometry showed CD8 T cell activation in blood but not in the primary tumors, 
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and that this correlated with an almost complete eradication of the metastases but a 
moderate to minor effect on the primary tumors. In contrast, the in vitro re-stimulation 
assay showed strong CD8 T cell responses to Mage-b and did not correlate with the 
effect of the combination therapy on the primary tumors at all. It is interesting that in 
many vaccine studies the in vitro re-stimulation assay is often used as measurement for 
effective vaccines, i.e. that they are able to induce CD8 T cell activation. However, this is 
only true in a non-tumor environment but as soon as these T cells reach the tumor, their 
function will be shut down by the immune suppression in the TME. Therefore, it is 
important to analyze the vaccine-induced immune responses in vivo in mice or humans 
with tumors. 
Another obvious result was that both combination therapies were more effective 
against the metastases than primary tumors. One of the reasons may be that the blood 
(#80%) contains many more MDSC than the primary tumors (#10%). However, primary 
tumors can be removed by surgery for most tumors, or by chemotherapy or radiation. In 
addition, our laboratory is investigating other non-toxic approaches such as killing 
primary tumor through cryoablation (freezing and thawing of tumor cells). We were able 
to completely eradicate primary tumor by this technique, and it appeared to be equally 
effective in humans (unpublished results). 
It is clear that one type of therapy will not be sufficient to eliminate metastatic 
cancer, and that multiple combination therapies, selected for the various types of cancer, 
and/or patient will be the future to combat metastatic cancer. The multiple pathways of 
Listeriaat, i.e. delivering TAA and !GC with extreme high efficiency into APC, infecting 
and converting MDSC when combined with curcumin or incorporated with !GC into an 
immune-stimulating phenotype producing IL-12, and infecting and killing tumor cells 
through ROS, with practically no side effects, makes Listeriaat highly attractive for cancer 
immunotherapy. Since Listeriaat infects tumor cells, also other approaches are possible 
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such as delivery of anti-tumor compounds in the tumor cells by Listeriaat. Indeed, our 
laboratory in collaboration with the laboratory of Dr. Dadachova (Microbiology and 
Immunology, Albert Einstein College of Medicine) has recently developed a radioactive 
Listeriaat, and we showed that Listeriaat efficiently delivered the radioactivity to the 
metastases, resulting in an almost complete elimination of the metastases in pancreatic 
cancer without noticeable side effects (Quispe-Tintaya et al, A non-toxic radioactive 
Listeriaat is a highly effective therapy against metastatic pancreatic cancer, PNAS, 
accepted). 
Last but not least, the age factor is an important issue because most cancer 
patients are old and elderly react les efficient to vaccines than young adults, due to T cell 
unresponsiveness91. This is mainly caused by lack of naïve T cells and to an increase in 
the number of MDSC in the TME at older age153-159. Paradoxically, the age factor is 
totally ignored in clinical trials and may partly be responsible for the absence of a real 
breakthrough in cancer vaccination. Since both combination therapies tested in this 
thesis targets MDSC and both are non-toxic, these combination therapies may be 
especially effective at older age. However, it is also clear that we still have a long way to 
go for the complete elimination of metastatic cancer at all ages. 
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Figure 1 Potential pathways of Listeria-
Mage-b and curcumin involved in anti-
tumor responses in mice with metastatic 
breast cancer (4T1 model). Mice will be 
treated with curcumin before and immunized 
with Listeria-Mage-b after tumor development. 
Curcumin will kill tumor cells and reduce IL-6 
production by tumor cells and MDSC. 
Reduction in IL-6 production will reduce 
immune suppression and restore T cell 
responses. Listeria-Mage-b will infect MDSC, 
tumor cells and APC (DC, macrophages, 
monocytes). Mage-b antigen will be delivered 
by Listeria inside the APC, then secreted at 
high levels in the cytoplasm and processed for 
assembling with MHC class I molecules for 
presentation on the membrane to CD8 T cells. 
Simultaneously, the combination of Listeria-
Mage-b and curcumin will reduce the number 
of MDSC, and induce IL-12 production in a sub 
population of MDSC in blood. Reduction in the 
number of MDSC will result in less immune 
suppression. IL-12 will induce T cell activation, 
resulting in the production of IFN!. Activated T 
cells will kill the tumor cells. In addition to this 
cascade of immune reactions the Listeria 
bacteria will infect and kill tumor cells through 
high levels of ROS, and infected tumor cells 
will be killed by Listeria-activated CD8 T cells 
(not shown). 
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Figure 2: Potential pathways of I-!GC-LM-Mb in 
anti-tumor responses in mice with metastatic 
breast cancer (4T1 model). Tumor-bearing mice will 
be immunized with Listeria-Mage-b incorporated with 
!GC (I-!GC-LM-Mb). I-!GC-LM-Mb will infect DC!+8 
DC (and other APC such as monocytes and 
mcrophages), and Listeria will produce Mage-b 
protein at very high levels in the DC. The Mage-b 
protein will be process and assembled with MHC 
class I molecules in the DC and presented on the 
membrane to CD8 T cells. Simultaneously, infection 
of CD8!+DC with I-!GC-LM-Mb will also lead to 
intracellular processing of the !GC and assembling 
with MHC-like molecule CD1d, and then presented 
on the membrane to NKT cells. This will result in the 
activation of NKT cells. The activated NKT cells will 
produce various cytokines that can stimulate NK cells 
and CD8 T cells. Most important cytokine is IFN#. The 
activated NK cells will produce IFN#, and further 
activation of CD8 T cells will occur. Finally, I-!GC-
LM-Mb will infect MDSC resulting in the production of 
IL-12. IL-12 activates CD8 T cells and NK cells. The 
activated CD8 T cells and NK cells will kill the tumor 
cells. In addition to this cascade of immune reactions 
the Listeria bacteria will infect and kill tumor cells 
through high levels of ROS, and infected tumor cells 
will be killed by Listeria-activated CD8 T cells (not 
shown). 
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SUMMARY 
 
The diagnosis of breast cancer has a reasonable prognosis, particularly when it is 
diagnosed in an early phase. Eliminating primary tumors by surgery, chemotherapy, or 
radiation is quite successful. However, for metastases there is no cure. Thirty percent of 
the breast cancer cases will progress into metastatic disease, but they cannot be 
removed by surgery or radiation, and usually become chemoresistant. However, 
preclinical and clinical studies have shown that cancer vaccination has an effect on 
metastases but that a real breakthrough is hampered by the strong immune suppression 
in the tumor microenvironment (TME). Therefore, in this thesis we focused on the 
treatment of metastatic breast cancer using an attenuated Listeria monocytogenes 
(Listeriaat)-based vaccine expressing tumor-associated antigen (TAA) Mage-b 
(developed earlier in our laboratory), combined with adjuvants to reduce immune 
suppression in the TME in order to improve the vaccine efficacy of Listeriaat-Mage-b. 
Listeriaat is a non-pathogenic bacterium, and was selected because of its great capability 
to deliver TAA into APC in vivo with high efficiency, its minimal side effects, and its ability 
to activate innate and adaptive immune responses. Listeriaat also kills tumor cells directly 
without harming normal cells. Moreover, the Listeriaat is naturally cleared by the immune 
system in normal tissues within 3-5 days. Mage-b was selected because Mage is 
homologous with its human homologue MAGE, which is expressed in 90% of all breast 
cancers. Here we have tested two different combination therapies in mice with 
metastatic breast cancer (4T1 model), and results demonstrated great promise of our 
approaches for the battle against metastases. 
 
The first combination therapy consisted of Listeriaat-Mage-b and curcumin. Curcumin is 
an Indian spice and able to reduce the production of interleukin (IL)-6. IL-6 is abundantly 
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produced by breast tumor cells and immune cells, and particularly in patients with 
metastatic breast cancer. IL-6 is one of the most important contributors to suppression of 
T cell responses in the TME. Curcumin also kills tumor cells directly. The second 
combination therapy consisted of Listeriaat-Mage-b and alphagalctosylceramide (!GC). 
!GC is a glycolipid that stimulates natural killer T (NKT) cells through its interaction with 
CD1d on CD8!+ dendritic cells (DC), which in turn generates a cascade of cytokine 
production that activates the innate and adaptive immune system, including the Mage-b-
specific T cells.  
 
In Chapter 2, we tested the combination of Listeriaat-Mage-b and curcumin 
therapeutically in mice with metastatic breast cancer, and found a dramatic reduction in 
the number of metastases by 85%, and reduced tumor growth by 60%, compared to 
non-treated mice. Since curcumin is consumed through food all over the world, we also 
tested whether administration of curcumin preventively (before tumor development) 
could have an advantage over curcumin therapeutically (after tumor development). It 
appeared that administration of curcumin before tumor development and Listeriaat-Mage-
b after tumor development resulted not only in a stronger decrease in the number of 
metastases (99%), but also significantly reduced tumor growth (75%), compared 
Listeriaat-Mage-b and curcumin after tumor development. Also curcumin alone 
preventively administered significantly reduced the number of metastases and tumor 
growth, although the combination was more effective. This suggests that consuming 
curcumin before tumor development may have an advantage over consuming curcumin 
after tumor development in the battle against metastatic breast cancer. This correlated 
with a significant reduction in the production of IL-6 by the primary tumors and immune 
cells in blood. Moreover, a sub population of myeloid-derived suppressor cells (MDSC), 
one of the most important contributors to immune suppression in the TME, was 
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converted by the combination therapy into an immune-stimulating phenotype producing 
IL-12, in correlation with significant improvement in T cell responses to Mage-b in the 
tumor-bearing mice. This combination therapy was not only highly effective against the 
metastases but also non-toxic as confirmed by pathological examination of spleen, 
kidney, liver, heart and lungs. 
 
In Chapter 3, Listeriaat-Mage-b and !GC was therapeutically tested in mice with 
metastatic breast cancer, and we found a dramatic reduction in the number of 
metastases (99%) compared to non-treated mice. However, this was accompanied with 
strong toxicity in the liver, which was not observed with Listeriaat-Mage-b or !GC alone. 
To address this problem we incorporated !GC into the cell wall of live Listeriaat bacteria 
expressing Mage-b (I-!GC-LM-Mb). Here, we demonstrate that repeated low dose 
administrations with I-!GC-LM-Mb in mice with metastatic breast cancer was equally 
effective against the metastases compared to vaccination with LM-Mb and !GC as a 
mixture, but without any visible toxicity as confirmed by pathology and survival studies. 
This was correlated with the activation of NKT cells, the generation of IL-12 production in 
MDSC, and significantly improved CD8 T cell responses to Mage-b and NK cell 
responses. Also tumor growth was significantly reduced but the combination was not 
better than the Listeriaat-Mage-b or !GC alone. Here we demonstrate for the first time 
that therapeutic treatment with live attenuated Listeriaat incorporated with !GC is highly 
effective against breast cancer metastases without toxicity.  
 
In conclusion, we have demonstrated that therapeutic vaccination with Listeriaat-Mage-b, 
when combined with adjuvants such as curcumin or !GC inhibits or converts immune 
suppression into immune stimulation, strongly reduced the number of metastases in 
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mice with metastatic breast cancer, in correlation with improved T cell responses to 
Mage-b and NK cell responses, without any visible toxicity. While the effect of both 
combination therapies was less effective against primary tumors, they could be of great 
values for second line therapy (after surgery, chemotherapy or radiation to remove the 
primary tumor), to prevent recurrence and the development of metastases. Because of 
the low toxicity, starting second line treatment in an early phase may further improve the 
clinical outcome.  
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SAMENVATTING 
 
De diagnose van borstkanker heeft een redelijke prognose, met name wanneer het is 
gediagnostiseerd in een vroege fase. Het elimineren van primaire tumoren door 
chirurgie, chemotherapie of bestraling is redelijk succesvol. Voor metastasen is er echter 
geen remedie. Dertig procent van de gevallen van borstkanker wordt uiteindelijk 
metastatisch. Metastasen kunnen niet worden verwijderd door chirurgie of bestraling, en 
worden meestal chemoresistant. Preklinische en klinische studies hebben echter 
aangetoond dat kanker vaccinatie een effect heeft op metastasen maar dat een echte 
doorbraak wordt belemmerd door de sterke immuun suppressie in de directe omgeving 
van de tumor. Dus, in deze thesis hebben we ons gericht op de behandeling van 
uitgezaaide borstkanker door gebruik te maken van een verzwakt Listeria 
monocytogenes (Listeriaat)-gebaseerd vaccin dat codeert voor de tumor-geassocieerde 
antigeen (TAA) Mage-b (dit vaccin was al eerder gemaakt in ons laboratorium), en we 
hebben het Listeriaat-Mage-b vaccine gecombineerd met specifieke stoffen om de 
immuun suppressie te kunnen onderdrukken ter verbetering van de werkzaamheid van 
het vaccin. Listeriaat is een verzwakte niet-pathogene bacterie, en wij hebben Listeriaat 
geselecteerd vanwege zijn grote capaciteit om TAA in antigen-presenterende cellen 
(APC) te leveren met hoge efficiëntie in vivo, zijn minimale bijwerkingen, en het 
vermogen om adaptieve en innate immuun responsen te activeren. Listeriaat doodt ook 
tumor cellen rechtstreeks zonder nadelige gevolgen voor normale cellen. Bovendien 
wordt de verzwakte Listeriaat geelimineerd door het immuun systeem in normale 
weefsels binnen 3-5 dagen, maar niet in the tumoren en metastases, omdat daar de 
Listeriaat beschermd worden door de sterke immune suppressie. Mage-b is geselecteerd 
in ons muizen model met metastatische borst kanker (4T1) omdat muizen Mage 
homoloog is met de menselijke MAGE, en omdat MAGE in 90% van alle borst kankers 
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voorkomt. Wij hebben hier twee verschillende combinatie therapieën in muizen met 
uitgezaaide borstkanker (4T1 model) getest en de resultaten suggeren dat onze aanpak 
veelbelovend is voor het bestrijden van metastasen. De eerste combinatietherapie 
bestaat uit Listeriaat-Mage-b en curcumin. Curcumin is een Indische specerij en is 
bekend vanwege het vermogen om de productie van het cytokine interleukine (IL)-6 te 
verminderen. IL-6 wordt overvloedig geproduceerd door borst tumor cellen en immuun 
cellen, en met name in patiënten met metastatische borst kanker. IL-6 is een van de 
belangrijkste cytokines die bijdragen aan de onderdrukking van T cell aktivatie in de 
directe omgeving van primary tumoren en metastases. Curcumin doodt ook tumor cellen 
rechtstreeks. De tweede combinatie therapie bestaat uit Listeriaat-Mage-b en 
alphagalctosylceramide (!GC). !GC is een glycolipid die natuurlijke killer T (NKT) cellen 
stimuleert door de interactie of !GC met CD1d in CD8!+ dendritische cellen (DC). 
Geaktiveerde NKT cellen kunnen een cascade van cytokine productie genereren, die op 
hun beurt innate and adaptive responsen activeert, inclusief the Mage-b-specific T 
cellen.  
 
In hoofdstuk 2, hebben we de combinatie van Listeriaat-Mage-b en curcumin 
therapeutisch (na de tumor ontwikkeling) getest in muizen met uitgezaaide borst kanker 
(4T1 model), en een drastische vermindering van het aantal metastasen (85%) en 
verminderde tumor groei (60%) gevonden in vergelijking met de onbehandelde muizen. 
Echter had curcumin zonder Listeriaat-Mage-b maar weinig therapeutisch effect. 
Aangezien curcumin over de hele wereld wordt geconsumeerd via voedsel, hebben wij 
ook getest of het preventief consumeren van curcumin een voordeel zou kunnen hebben 
in vergelijking met het therapeutisch consumeren van curcumin. Het bleek dat preventief 
consumeren van curcumin in combinatie met het toedienen van Listeriaat-Mage-b in een 
therapeutisch setting niet alleen resulteerde in een sterke daling van het aantal 
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metastasen (99%), maar ook aanzienlijk tumor groei verminderde (75%), in vergelijking 
met curcumin and Listeriaat-Mage-b beiden therapeutisch toegediend. Ook had curcumin 
zonder Listeriaat-Mage-b een significant preventief effect op de metastases and tumoren. 
Dit suggereert dat het preventief consumeren van curcumine een voordeel zou kunnen 
hebben ten opzichte van het therapeutisch consumeren van curcumine in de strijd tegen 
uitgezaaide borst kanker. Dit resultaat correleerde met een aanzienlijke vermindering in 
de productie van de IL-6 in de primaire tumoren en immune cellen in het bloed. 
Bovendien werd een sub-populatie van myeloide-afgeleide suppressor cellen (MDSC), 
een van de belangrijkste immuun cellen die bijdragen aan immuun suppressie in the 
direct omgeving van de tumor, veranderd door onze combinatie therapie in immuun-
stimulerende cellen door het produceren van IL-12 (activeert T cellen), in correlatie met 
een significante verbetering in T cel responsen tegen het Mage-b antigen in de tumor 
cellen of primaire tumoren en metastases. Deze combinatie therapie was niet alleen een 
zeer effectief middel tegen de metastasen maar was ook niet-toxisch, zoals bevestigd 
door pathologisch onderzoek van de milt, de nieren, lever, hart en longen. 
 
In hoofdstuk 3, hebben we Listeriaat-Mage-b en !GC therapeutisch getest in muizen 
met uitgezaaide borst kanker en ook hier vonden we een drastische vermindering in het 
aantal metastasen. Dit ging echter gepaard met een sterke toxiciteit in de lever, wat niet 
werd waargenomen wanneer Listeriaat-Mage-b of !GC gescheiden werd toegediend. 
Om dit probleem aan te pakken hebben we !GC geincorporeerd in de cel wand van de 
verzwakte Listeriaat bacteriën die Mage-b expresseren (I-!GC-LM-Mb). Hier laten we 
zien dat herhaalde toedieningen van lage dosis I-!GC-LM-Mb in muizen met uitgezaaide 
borst kanker net zo effectief was tegen de metastasen als het mengsel van LM-Mb en 
!GC, maar nu zonder enige zichtbare toxiciteit. Dit was gecorreleerd met het aktiveren 
van de NKT cellen, het genereren van de IL-12 productie in MDSC, en een aanzienlijk 
 151 
verbetering in de CD8 T cel en NK cel responses in bloed. Ook de tumor groei was 
aanzienlijk verminderd, maar I-!GC-LM-Mb was niet significant beter dan de Listeriaat-
Mage-b of !GC alleen. Hier tonen we voor de eerste keer aan dat de therapeutische 
behandeling met levende maar verzwakte Listeriaat geincorporeerd met !GC een zeer 
effectief middel is tegen de borst kanker metastasen zonder toxiciteit.  
 
Samengevat, wij hebben aangetoond dat therapeutische vaccinatie met Listeriaat-Mage-
b, wanneer gecombineerd met curcumin of geincorporeerd met !GC, de immuun 
suppressie kunnen remmen of veranderen in immuun stimulatie, en het aantal 
metastasen in muizen met uitgezaaide borst kanker sterk vermindert, in correlatie met 
significant verbeterde T cel responses tegen Mage-b en NK cel responses, zonder enige 
zichtbare toxiciteit. Terwijl het effect van beide combinatie therapieën minder effectief is 
tegen primaire tumoren, kunnen ze van grote waarden zijn voor “tweede lijn” therapie 
(na door chirurgie, chemotherapie of straling verwijderen van de primaire tumor), ter 
voorkoming van de ontwikkeling van metastasen. Vanwege de lage toxiciteit, kan het 
starten van de tweede lijn behandeling in een vroege fase beginnen om daardoor de 
klinische resultaten verder te verbeteren. 
  Manisha Singh 
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List of Abbreviations 
APC       Antigen-presenting cell  
!GC      Alphagalactosylceramide  
CCL   Chemokine (C-C) motif ligand 
COX   Cyclooxygenase 
CTL   Cytotoxic T lymphocytes 
DC        Dendritic cell  
DCIS    Ductal carcinoma in situ 
DMEM      Dulbecco's Modified Eagle's Medium  
ER          Estrogen Receptor  
FBS       Fetal bovine serum  
FGF   Fibroblast growth factor 
gMDSC      Granulocytic myeloid-derived suppressor cells 
GM-CSF    Granulocyte-macrophage colony-stimulating factor  
iNOS      Inducible nitric oxide synthetase  
IL        Interleukin  
I-!GC-LM-Mb    LM-Mb incorporated with !GC 
IDC    Invasive ductal carcinomas  
ILC   Invasive lobular carcinoma  
IBC    Inflammatory breast carcinoma  
IFN           Interferon  
LLO        Listeriolysin O  
LM           Listeria monocytogenes 
LM-Mb      Listeria-Mage-b  
LCIS   Lobular carcinoma in situ  
MAGE       Melanoma-associated antigen 
MDSC       Myeloid-derived suppressor cells 
mMDSC     Monocytic myeloid-derived suppressor cells  
MCA         Methylcholantrene  
MHC      Major histocompatibility complex 
MLN       Mesenteric lymph nodes 
MMP   Matrix metalloproteinase 
NK        Natural killer   
NKT       Natural killer T  
NFkB        Nuclear factor kappa-light-chain-enhancer of activated B cells 
PDGF   Plateled-derived growth factor 
PR         Progesterone receptor  
PRR         Pattern recognition receptors  
prfA           Positive regulatory factor  
ROS       Reactive oxygen species 
STAT3       Signal transducer and activator of transcription 3 
TME      Tumor microenvironment 
TAA        Tumor-associated antigen  
TAM       Tumor-associated macrophages  
TN          Triple-negative   
TNBC      Triple negative breast cancer  
TGF-"        Transforming growth factor beta 
VGEF        Vascular endothelial growth factor  
